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Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited form 
of renal disease, and is characterised by the formation of fluid-filled cysts within organs, 
particularly in the kidneys. The two genes that are mutated in ADPKD, PKD1 and PKD2, 
encode proteins in a plasma membrane complex that facilitates calcium ion release in the cell. 
Patients typically have an inherited mutation in one of these genes from birth and it is 
postulated that a second hit in the same gene is required for pathogenesis. Changes in 
downstream signalling pathways then give rise to the cysts, physically limiting the function 
of the kidney, and without intervention can lead to renal failure. Mutations in the second 
allele have been found to be responsible for the second hit in some but not all cysts. We 
postulate that this “second hit” could also be caused by epigenetic mechanisms, particularly 
involving changes in DNA methylation. Epigenetic modifying drugs have been shown to 
reduce cyst formation and limit the pathology of the disease. The use of a targeted delivery 
system conjugated to an epigenetic modifying drug could ensure the drug concentration is 
sufficient within the renal tissue, with minimal exposure elsewhere in the body, reducing side 
effects. Conjugates such as this could initially be most effectively be tested in a small animal 
model, such as in mice. 
To facilitate these types of studies, we have investigated DNA methylation in two regions of 
the mouse Pkd1 gene. Bisulfite sequencing of kidney DNA samples from wildtype mice, and 
the del34 Pkd1 mouse model heterozygous for a Pkd1 mutation, were performed. We found 
that the promotor CpG island was unmethylated whereas the gene body region examined was 
hypermethylated in both Pkd1 heterozygous and wildtype mouse kidneys. However, 
quantitative PCR expression analysis revealed consistently higher expression of the Pkd1 
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gene in Pkd1 heterozygous samples when compared to wildtype. Hematoxylin and eosin 
staining of mouse kidneys sections revealed at least one confirmed cyst in a Pkd1 
heterozygous sample, but cysts are considerably fewer in number when compared with the 
human disease.  
 
To extend the limited data available on the methylation landscape in human PKD1, we have 
performed reduced representation bisulfite sequencing (RRBS) on two ADPKD human 
kidney samples, and three wildtype kidney samples. In contrast to the mouse data, we found 
methylation differences in the PKD1 gene in ADPKD samples, when compared to wildtype 
kidney tissue, and changes in other key genes involved in cystogenesis. These data further 
support a potential role for DNA methylation in ADPKD pathogenesis. 
 
To be able to target a potential methylation difference specifically in the kidney, as a 
therapeutic option for ADPKD, we have investigated the ability of the galectin-3-avid (C3-
G12) binding peptide to specifically localise to the kidney. We injected the peptide bound to 
a Cy3.5 fluorescent probe into wildtype mice. We observed that the C3-G12-Cy3.5 conjugate 
accumulated in the mouse kidneys and was retained there for at least 30 minutes. In contrast, 
little to no fluorescence was observed in the heart, liver, lungs and spleen. These data suggest 
that the C3-G12 peptide could be used in a selective delivery mechanism for future therapies. 
This research provides new data on the mouse and human methylation landscapes in ADPKD 









ADPKD Autosomal Dominant Polycystic Kidney Disease 
ARPKD Autosomal Recessive Polycystic Kidney Disease 
AMP  Ampicillin 
DNMT DNA methyltransferase 
E.coli  Escherichia coli 
FDA  USA Food and Drug Administration 
LB   Lysogeny/Luria Broth (both terms acceptable) 
LBAA  LB + ampicillin + agar 
HAT  Histone acetyltransferase 
HDAC  Histone deacetylase  
HPRT  Hypoxanthine-guanine phosphoribosyltransferase 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
PC-1  Polycystin-1 
PC-2  Polycystin-2 
PCR  Polymerase chain reaction 
PKD  Polycystic Kidney Disease 
RRBS  Reduced representation bisulfite sequencing 
SOC  Super optimal broth containing chloride 
TAE  Tris-acetate buffer 
TSA  Trichostatin A 
QPCR  Quantitative polymerase chain reaction 
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Chapter 1: Introduction 
1.1 Ciliopathies 
Primary cilia are immotile extracellular appendages found on several different cell types 
throughout the vertebrate body. Primary cilia contain microtubules arranged in a 9+0 pattern 
(axoneme), where all nine microtubule pairs are equally spaced around the outer edge of the 
cilia. They do not possess the central pair of tubules (9+2) found on motile cilia1 and 
therefore are not able to facilitate movement of fluid and liquids on their own (unlike motile 
cilia that are able to generate movement of fluid). In kidneys, primary cilia are found on most 
cells of the kidney including the epithelial cells of the renal tubules, Bowman’s capsule and 
collecting ducts2 and can be up to three microns in length in both human and rodents3. Renal 
cilia function as a method of detecting changes in the extracellular environment such as the 




Figure 1.1: Primary cilia in the kidney respond to changes in renal flow and mediate downstream pathways5. 
PC-1 = Polycystin-1, PC-2 = Polycystin-2. 
 
Disruptions in the cilia structure, function or related complexes and gene pathways can result 
in a broad range of renal diseases known as ciliopathies, often with overlapping phenotypes1. 
Examples of ciliopathies include syndromes such as Bardet-Biedl, Joubert and Meckel-
Gruber, which have a variety of symptoms affecting various organs in the body including: 
retinal degradation; laterality defects; intellectual disability; cerebellar vermis hypoplasia; 
encephalocele; polydactyly; obesity; bone deformation and ectodermal dysplasia6. 
Hepatobiliary disease and cystic kidneys are found in most ciliopathies and are the primary 
symptoms in autosomal polycystic kidney disease.  
Autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic 
kidney disease (ARPKD) are differentiated by their mode of inheritance and the genes 
affected, although diagnosis and separation of these two diseases by examination of clinical 
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symptoms is difficult, particularly for neonatal patients7. Family history is often combined 
with histological, ultrasound and more recently MRI and genetic testing to provide a more 
accurate diagnosis8,9.  
 
1.2 Autosomal Dominant Polycystic Kidney Disease 
Autosomal dominant polycystic kidney disease (ADPKD) is one of many cystic kidney 
ciliopathic diseases characterised by the formation of fluid-filled cysts within the kidney 
nephron10. ADPKD is the most common form of inherited kidney disease, ranging from 1 in 
400 to 1 in 1000 individuals affected worldwide11. Cysts continue to grow over the life of the 
patient with little to no symptoms, until renal function becomes impeded in the fourth and 
fifth decade of life, with no treatment available12. Factors including genotype, age, sex, 
kidney function and kidney volume can be used to predict disease progression9.  
Other clinical features include cystic livers, hypertension and an increased risk of cardiac 
diseases and intracranial aneurysms13. 
In 85% of ADPKD cases the gene PKD1 is mutated, whereas the remaining 15% of cases are 
caused by PKD2 mutations14. Typically patients inherit a single copy of one of the mutated 
genes15. Due to the high costs of PKD1 analysis, genetic testing is generally restricted to 
neonatal diagnosis16, kidney transplant assessment17 and cases with little family history 
available9. Patients with PKD2 mutations have been shown to have the longest predicted life 
expectancy18, with PKD1 non-truncating and truncating mutations having intermediate and 
the worst prognosis respectively11. 
Previous publications had theorised about a possible PKD3 gene. Where five published 
families with ADPKD did not show any PKD1/PKD2 linkage19,20,21,22,23, re-analysis of these 
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cases revealed misdiagnosis and sample contaminations, with little evidence to support the 
existence of PKD324. 
PKD1 is located at chromosome 16p13.3 and contains 46 exons spanning a 12,909 base pair 
(bp) coding region25. Exons 1-33 have been duplicated and have ~98% homology with six 
pseudogenes located at 16p13.126. PKD2 is located at 4q21 and contains 15 exons over a 
2904 bp coding sequence27. 
 
1.3 Polycystin-1 and -2 
PKD1 and PKD2 encode the polycystin-1 and -2 proteins respectively. Polycystin-1 (PC-1) 
has 4302 amino acids (aa) consisting of an extracellular N-terminal of ~3000 aa, 11 
transmembrane domains and an intracellular C-terminal tail of 198 aa28. Polycystin-2 (PC-2) 
consists of 968 aa, forming six transmembrane domains and intracellular N and C terminal 
domains27. The PC-2 protein acts as a nonselective Ca2+ cation channel on the plasma and/or 
the endoplasmic reticulum membrane. 
Within the kidneys, the PC-1 and PC-2 C-terminal domains can interact to form a complex on 
the renal tubule epithelial cell cilia membrane29 (Figure 1.1), where PC-1 acts as a 
mechanosensor that responds to renal flow and subsequently regulates Ca2+ ion flow via PC-
25. Additionally, Ca2+ is theorised to be released from inside the cell by an interaction 
between the PC-1 C-terminus and PC-2 proteins found on the endoplasmic reticulum30. 
Increased levels of intracellular Ca2+ then activate downstream pathways that maintain the 
epithelial phenotype31.  
Polycystin-1 contains an auto-proteolytic site that is able to cleave off the extracellular N-
terminal domain (Figure 1.2), allowing it to either be released or tethered to the remaining 
protein15. Both cleaved and uncleaved proteins are required for full function of PC-132. The 
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C-terminus of PC-1 is responsible for interactions with G-proteins and PC-2 during Ca2+ 
signalling33. The C-terminus of PC-1 is also able to be cleaved into two distinct products 
(Figure 1.2) which both interact with transcription factors in the nucleus34, 35. 
 
Figure 1.2: The polycystin-1 and -2 proteins exhibit several different isoforms on the membrane and within the 
renal tubule epithelia.  A I The entire uncleaved membrane-bound PC-1 protein. II The cleaved N-terminus 
fragment (NTF), which is then able to anchor to the remaining membrane bound section of the protein (III). IV 
and V The cleaved C-terminus fragment (CTF) and C-terminus tail (CTT) of PC-1. Their specific role in 
pathogenesis is not yet well understood. B The PC-1 and PC-2 complex found on the renal epithelial cell cilia. 
The N-terminus of PC-1 acts as a mechanosensor for renal flow, which then activates the opening of the PC-2 
Ca2+ ion channel by the coupling of the C-terminus. C PC-1 is also able to couple to PC-2 found on the 
endoplasmic reticulum to allow further Ca2+ into the cytosol. Figure from Boletta (2009)28, reprinted with 
permission from Pathogenetics (2016). 
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Several key characteristics of cystogenesis have been noted in both human studies and animal 
models: thickening of the epithelial cell basement membrane; increased cell death by 
apoptosis; proliferation of cystic epithelia; and pumping of renal fluid to the cyst28. 
The PC-1 and PC-2 proteins are able to regulate and interact with several major gene 
pathways that are directly involved in the development of these cystic characteristics. PC-1 is 
able to regulate the mTOR pathway, which is involved in cell proliferation and has been 
shown to be misregulated in ADPKD36. The PC-1/PC-2 complex has been shown to regulate 
the cell cycle via the JAK/STAT pathway, where inhibition of STAT6 is able to limit cyst 
growth and preserve renal function in a PKD mouse model37. PC-1 also interacts with JAK2 
which induces the p21 protein, which in turn inhibits the cell division kinase Cdk2 and 
triggers cell cycle arrest38. Wnt/β-catenin signalling, which is involved in development and 
epithelial cell differentiation, is believed to be directly influenced by renal tubular lumen 
flow39 and by polycystin-140. Ca2+ signalling has been shown to regulate the cAMP pathways 
which have roles in cell proliferation, differentiation, transcription and fluid transport41. 
Mismanagement of major cilia developmental pathways Hedgehog and Notch have both been 
shown to be involved in cancer research and may play a role in ADPKD42. 
 
1.4 Mechanisms of disease  
Individuals with ADPKD have one inherited non-functioning copy of either PKD1 or 
PKD224. Mouse models with both inactivated copies of Pkd1 or Pkd2 show embryonic 
lethality43, suggesting that the quantity of PC-1 and PC-2 expressed by a heterozygote is 
sufficient for development. Consequently, a “genetically recessive” model of cystogenesis 
has been proposed where the inherited mutation is combined with somatic loss of the second 
copy of the gene. This hypothesis is supported by the observed small number of nephron cells 
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that actually become cystic (~1%) and the varying quantity of cysts found between patients44. 
 
Two models have been established to explain pathogenesis of cyst development. The first is 
known as the “Second-hit hypothesis”, where somatic epithelial cells develop secondary 
“hits” that eliminate the second functioning copy of PKD1 or PKD245. In support of this, the 
Pkd2Ws25 mouse model, which contains a knockout of one allele of PKD2 and an inserted 
element that generates somatic recombination in the second PKD2 allele (where the inserted 
element can somatically produce either a PKD2 wildtype or knockout second allele), has 
been shown to correlate somatic loss of Pkd2 with cyst formation46. Additionally, secondary 
mutations have been found in some studies47,48,49, but not in all cyst examined. One paper has 
reported heterozygous mutations found in both PKD1 and PKD2, suggesting a potential for 
additional “trans-heterozygosity” causation for cystogenesis50. 
 
Another idea put forward is one of haploinsufficiency of PKD1 and PKD2. In this model, if 
the expression level of either gene falls below a threshold needed to maintain the epithelial 
phenotype in somatic cells, then cystogenesis occurs in that cell. This model is supported by 
studies where the lowering of Pkd1 expression in a mouse model has initiated 
pathogenesis51,52. 
 
Conversely, studies have shown that some human cystic kidneys show overexpression of 
PKD153, and induced overexpression of Pkd1 or Pkd2 in mice can lead to pathogenesis of 




1.5 Cystogenesis  
Cystogenesis occurs when the epithelia lining the renal tubules, which contain an inherited 
mutated PKD1 or PKD2 allele, undergoes the aforementioned ‘second hit’ of the second 
allele or the gene expression falls below a threshold (haploinsufficiency)45,51. Tissue injury 
and repair processes then alter the structural integrity of the cells, which cannot maintain their 
correct epithelial phenotype due to the loss of polycystin-1 or -2, and subsequent 
misregulation of their downstream pathways. The epithelial cells then proliferate clonally48 
and activation of the cAMP pathway drives fluid secretion into the cysts41. Increased 
adhesion to collagens and laminin alter the extracellular matrix56, eventually leading to 
fibrosis and invasion by inflammatory cells57. 
 
Figure 1.3: The currently understood pathway to cystogenesis in ADPKD. Epithelial cells first undergo a 
second hit or haploinsufficient gene expression for PKD1 or 2. Misregulated gene pathways and 
hyperproliferation then allow the epithelia to lose basal polarity and alter fluid management. This can be 
accelerated by renal injury. Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Nephrology (Happé et al., 2014)57, copyright (2014). 
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1.6 Animal models for polycystic kidney disease 
Animal models provide an excellent foundation to examine the genetic and pathological 
mechanisms in polycystic kidney diseases. Animal models can be developed in two forms: 
those where spontaneous disease is discovered in a species and a breeding stock is 
maintained; and those that were created by genetic manipulation of specific genes. 
ADPKD and ARPKD have spontaneously developed in several species including dogs58,59, 
cats60,61, goats62 and sheep63. Several spontaneous mice and rat models have also been 
identified, with varying phenotypes and renal pathology64. However, few, if any spontaneous 
models are PKD1 or PKD2 mutants. Instead mutations in these animals are often found to be 
in related genes involved in the development or function of the primary cilia64. 
Model organisms created by genetic engineering for research purposes often include 
zebrafish and rodents, due to the size, cost, existing genome knowledge and ease of use for 
genetic research. Zebrafish models have been used for a range of studies including 
knockdowns65 and mutational studies66 to identify developmental and morphological 
pathways that pkd1 or pkd2 may be involved in. 
Engineered rodent models have long been used to study the pathological and genetic basis for 
diseases including ADPKD. There exists many different rodent models (Table 1.1). In 
contrast to the dominant human disease, mouse models with heterozygous mutations in Pkd1 
or Pkd2 develop only small cysts with renal function largely uninhibited, depending on the 
specific model67. Homozygous mutants are generally embryonically lethal57.  Other models 
exist that more closely match the human phenotype but utilise inducible secondary hits using 
Cre-Lox technology57. Animal models have also been established to examine PKD1 or PKD2 
under and overexpression, with renal cysts being induced in both of these conditions51,68,69. 
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Inducible and conditional mouse models display a disease phenotype more similar to human 
ADPKD than double knockouts, however these models do not reflect a spontaneous somatic 
second hit that is proposed as a mechanism for the disease. To investigate the mechanism 
behind the second hit, researchers must use one or more of the limited number of 
heterozygous knockout mice available. 
Table 1.1: A list of published Pkd1 and Pkd2 rodent models for polycystic kidney disease 
Knockouts 
Pkd1 Pkd1(del34) Pkd1(del17) Pkd1(del2–6) Pkd1(del2–11) 
  Pkd1(Bdgz) Pkd1(null) Pkd1(βgal–null) Pkd1(del17−21/geo) 
Pkd2 Pkd2(null) Pkd2(LacZ) Pkd2(d3)   
 
    Conditional knockouts 
Pkd1 Pkd1flox/−:Ksp-Cre Pkd1flox:γGT.Cre Pkd1cond:MMTV.Cre Pkd1flox:NestinCre 
  Pkd1flox:ATCB-Cre Pkd1flox:Pkhd1-Cre Pkd1lox:Tie2Cre Pkd1con/−:Tie2-Cre 
  Pkd1lox:SM22Cre Pkd1cond/−:Meox2-Cre Pkd1KO/cond:Sm22α-Cre   
Pkd2 Pkd2F:Pkhd1-Cre Pkd2f3:γGT.Cre Pkd2fl:Wnt1Cre Pkd2cond/cond:Meox2-Cre 
     Inducible (conditional) knockouts 
Pkd1 Pkd1cond:R26CreER Pkd1lox:tam-KspCad-CreERT2 Pkd1flox:Mxi-Cre Pkd1cond:tam-Cre/Esr1 
  Pkd1flox:pCX-CreER Pkd1tm1Gztn:R26CreERT2 
 
  
Pkd2 Pkd2fl:pCxCreER Pkd2f3:Pdx1-Cre-ER™ Pkd2f3:Mx1-Cre   
          
     Hypomorphic 
Reduced expression Pkd1(nl) Pkd1(L3) Pkd1miR TG   
  
   
  
Unstable expression Pkd2(WS25) Pkd2(WS25/WS186) Pkd2(nf3)   
  
   
  
Missense mutation Pkd1(RC) Pkd1(V) Pkd1(mBei)   
     Overexpression of human protein 
PKD1 PKD1(extra) PKD1TAG hPKD1 TPK   
  
   
  
PKD2 hPKD2 TG hPKD2 hPKD2(1/703)   
 
The del34 mouse model used in this study is highlighted. The table was adapted from (a review of individual 
models can be found in) Happé and Peters (2014)57. 
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1.7 Epigenetics and ADPKD 
Epigenetics is described as heritable changes to gene expression with no change to the DNA 
code itself. Epigenetic regulation is now known to be critical for appropriate gene expression 
in development and major regulatory pathways. 
Two key mechanisms in the epigenetic modification of gene expression are DNA 
methylation, where methyl groups are added to the DNA base cytosine when followed by a 
guanine (a CpG), and histone post translational modifications70. 
These mechanisms regulate gene expression by altering chromatin conformation, which in 
turn allows or restricts access to the DNA by transcription factors (reviewed by Liyanage et 
al., (2013)71. 
 
1.7.1 Histone modifications 
Histones are a series of proteins (H3, H4, H2A, H2B and H1) that form a histone octamer 
complex that DNA is ‘wrapped’ around to form the nucleosome and chromatin 
superstructure. Tail-like N-terminal domains extend from the histone proteins and post-
translational modification to these tails can alter the physical structure of chromatin, to allow 
or restrict access to the DNA by transcription factors72, or for repair and replication73. The 
most common of the histone modifications are acetylation, methylation and phosphorylation, 
which are generally associated with open chromatin and gene expression. Deacetylation, 
demethylation and desphosphorylation are instead associated with closed chromatin and gene 
repression74. 
Histone methylation is controlled by histone methyltransferases and demethylases. 
Methylation of specific histone lysine and arginine amino acids provide binding access for 
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histone reader proteins75, which in turn can change the conformation of the chromatin. The 
specific lysine that is targeted for histone methylation often determines the nature of the 
chromatin modification. For example, methylation of histone H3 lysine 36 (H3K36) is 
associated with gene activation, whereas H3K27 methylation is associated with gene 
silencing. Histone arginine methylation regulates protein-protein interactions76. Together, 
histone methylation has been shown to be involved in cell fate, X inactivation, transcriptional 
regulation, RNA metabolism and DNA repair77. In cancer, histone methylation is often 
dysregulated and is linked to further misregulation of chromatin78. 
Phosphorylation of histones H1 and H3 is unique, as while it is associated with gene 
activation, it has also been shown to play a key role in chromosome condensation during cell 
mitosis79. Similar studies have suggested that phosphorylation modifications of histones 
appear to be dynamic in nature and when combined with additional marks such as 
acetylation, can be involved in both gene expression based chromatin remodelling and 
chromatin condensation, depending on the specific cell type and regulatory pathway80. 
Histone acetylation of lysine residues on the tail domain is regulated by histone 
acetyltransferases (HATs)81. HATs are divided into Type A and Type B classes based on 
their localisation in the cell82. Acetylation marks are associated with active DNA and are 
often found in transcriptionally open promotor regions of the genome83. Removal of 
acetylation marks from the histone tail by histone deacetylates (HDACs) are instead 
associated with gene repression. Four classes of HDACs exist, with many implicated in 
development and major gene pathway regulation82. 
HDACs have been shown to be important for Pkd184 function as well as being involved in 
flow-induced calcium signalling85. 
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HDACs have been the target of therapy development in recent years through the use of 
HDAC inhibitors, with a number having been developed and approved by the USA Food and 
Drug Administration (FDA) for use as anti-cancer agents86.  
The effectiveness of HDAC inhibitors on ADPKD models has been examined in several 
studies, where HDAC inhibitors valproic acid (VPA) and trichostatin A (TSA) have been 
shown to reduce renal function loss and cyst development in mouse models12,85. TSA acts by 
inhibiting HDAC5, which is regulated by renal fluid flow and Ca2+ signalling pathways and 
activates gene expression of myocyte enhancer factor 2C (MEF2C)85, which is involved in 
myocardium hypertrophy. Injection with TSA partially restored epithelial phenotype in cyst 
lining cells85. An additional study by Fan et al., (2012)87 identified that TSA downregulates 
epithelial cell proliferation and is able to reduce cystogenesis in mouse embryonic kidney 
cells. VPA functions by inhibiting class 1 HDACs, and was identified in a chemical modifier 
screen in zebrafish, where VPA partially restored the body curvature phenotype seen in pkd2 
mutants and reduced cyst formation in both zebrafish pkd2 mutants and Pkd1flox/flox;Pkhd1-
Cre* conditional knockout mice12. 
 
1.7.2 DNA methylation 
DNA methylation occurs at ~70-80% of CpGs across the genome, with concentrations of 
these (known as CpG islands) located within gene promotors, transcription start sites and 
enhancer regions71. Cytosines are methylated by DNA methyltransferases (DNMTs) during 
development and after DNA replication88. 
Methylation of DNA is historically known to function as a targeted suppression of specific 
genes and pathways, including X inactivation89, imprinted genes during development90 and 
transposon regions91. Gene promotor methylation is associated with gene repression and 
 
* Pkhd1 is the gene mutated in human Autosomal Recessive PKD 
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restriction of transcription factors to the DNA92,93. Gene body methylation, in contrast, has 
more recently been associated with an increase in gene expression88,94, by potentially 
suppressing unwanted transcriptional noise and regulating enhancers and silencers95,96. 
Increased gene body methylation has also been associated with an accumulation of  DNA 
mutations97.  
Misregulation of DNA methylation may contribute to the pathogenesis of many diseases, and 
has been a popular topic in cancer research in the last decade, as reviewed by Fukushige and 
Horii 92. Many tumour suppression genes that regulate key cellular pathways such as cell 
cycle control, DNA repair and apoptosis have been identified as being suppressed by DNA 
methylation in cancers98. Inversely global hypomethylation and the resulting inappropriate 
activation of oncogenes has also been observed in many cancers99. 
The reversible nature of DNA methylation has also been a target for treatment development. 
Synthetic nucleotides, 5-Aza-2deoxycytidine and 5-Azacytidine replace cytosine in the DNA 
and block DNMT activity, globally reducing the quantity of methylation after each 
consecutive cell division100,101. Treatment of tumours with these two drugs has shown to be 
effective and promote long-term stability of transcriptionally open promotors102,103. 
 
1.8 DNA Methylation and ADPKD 
 
While literature has explored the role of histone modifications and the greater field of 
epigenetics in ADPKD, almost no research exists on DNA methylation. 
A paper by Woo et al., (2014)104 used bisulfite treatment combined with global sequencing 
and expression analysis on human ADPKD samples to determine if there are any correlations 
between DNA methylation and gene expression. They found that 91% of all methylation 
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changes in the ADPKD samples, when compared to wildtype, appeared to be 
hypermethylation, with 61% associated with genic regions. Expression analysis revealed a 
correlation between PKD1 gene body hypermethylation and a decrease in PKD1 expression. 
Surprisingly, promotor regions were reported between 0-1% of all intergenic methylation 
changes. This is unusual as historically promotor hypermethylation, rather than the gene 
body, is associated with a decrease in gene expression93, though this has not been seen in all 
cell types105. Other studies have reported a correlation between lower gene expression and an 
increase in 3’ gene body methylation106. Keys genes that were found to be hypermethylated 
in the ADPKD samples were involved in calcium signalling, ion transport, Notch signalling, 
and the PKD1 gene itself, particularly in the gene body region. Madin-Darby canine kidney 
(MDCK) cell lines, which are used as a model of in vitro cyst formation as they proliferate 
and form cysts when suspended in a collagen gel107, were treated with 5-Aza-2deoxycytidine 
and the DNMT inhibitor zebularine. Cyst formation and Pkd1 methylation was reduced and 
this was correlated to an increase in Pkd1 expression. 
A more recent paper by the same author108, used the same samples and similar techniques to 
show that the mucin-like protocadherin (MUPCDH) gene is hypermethylated in its promotor 
region, particularly in cyst-lining cells. Increased cell proliferation was correlated with the 
decrease in MUPCDH expression.  
Methylation patterns have been shown to change with age in certain regions of the 
genome109. This could possibly contribute to the tendency for the development of ADPKD 




1.9 Bisulfite Sequencing 
A variety of techniques have been developed to analyse DNA methylation, with the aid of 
next-generation sequencing, including: methylation-sensitive restriction enzyme digest, 
methylated DNA immunoprecipitation and bisulfite sequencing, amongst others. 
Methylation-sensitive restriction enzyme digestion is one technique, where specific 
restriction enzymes are used that are able to cleave the DNA at unmethylated cytosines. 
Methylated cytosines are therefore preserved in the sample and are able to be amplified when 
followed by PCR and other analyses110. 
Another technique involves methylated DNA immunoprecipitation, which utilises antibodies 
specific for methylated cytosines. It can be combined with microarray or next-generation 
sequencing for chromosomal or genome wide analysis111.  
Bisulfite sequencing is a technique used to identify methylated cytosines within a section of 
DNA (Figure 1.4). The DNA is treated with sodium bisulfite, which converts all cytosines 
into uracil unless they are protected by an attached methyl group. A PCR reaction then results 
in conversion of the uracils to thymine. Any cytosines present in the sequenced DNA, are 
ones that were originally methylated112. Because of the risk of PCR bias introduced by the 
potential for methylated cytosines to alter primer binding, primers must be carefully designed 
to avoid any CpGs within their binding sequence or be redundant so that both methylated and 
unmethylated cytosines will be recognised.  
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Figure 1.4: Bisulfite sequencing reveals all methylated CpGs on the DNA after PCR and sequencing. 
Methylated cytosines (Red) are protected from the bisulfite reaction which renders all unmethylated cystosines 
into uracil. Uracil is then converted into thymine after PCR. All methylated cytosines in the initial sequence are 
preserved as cytosines after sequencing112. Pkd1 promotor sequence obtained from Ensembl browser 83113. 
 
Bisulfite sequencing has also been adapted using next-generation sequencing techniques to 
examine larger spans of DNA at much greater depth114. Whole genome bisulfite sequencing 
(WGBS-seq) has been used to examine entire methylomes of several cell human cell 
lines115,116,117, cancer samples118,119,120 and methylomes of other species121,122. 
Due to the high cost of WGBS-seq, several other techniques have been developed for more 
specific applications, as reviewed by Lee et al., (2013)123. 
One such technique is reduced representation bisulfite sequencing (RRBS), where a 
representative selection of the genome CpG islands are treated and sequenced by use of 
methylation-insensitive restriction enzymes, such as MspI124. Size selection of the DNA 
library can then eliminate small fragments, which can be redundant and difficult to align, and 








the entire genomic methylation landscape that is enriched for CpG islands. The sizes selected 
depend on the requirements of the specific study and comes with a trade-off between depth 
and coverage125.  
 
1.10 Developing a treatment for ADPKD 
There exist no treatments for ADPKD on the market. Patients at later stages of the disease 
generally undergo dialysis and eventually renal transplantation. There exists potential for 
drug therapies that target specific gene pathways, such as STAT637 or more generalised 
treatments that target aspects of the disease progression. For example a therapy could be used 
to reduce epithelial proliferation to reduce cyst growth12 or rescue renal function long enough 
to allow the patient sufficient quality of life for the remaining decades of their lives. 
Human clinical trials have been performed in the past126 and several are currently in progress 
in several countries127. However, effective treatment of kidney disease often require high 
intra-renal drug concentrations which can also expose the patient to significant side effects128. 
A way to avoid this is a targeted delivery system that is able to deliver the drug directly to 
where it is needed within the kidneys. There are many different methods developed to 
achieve this, with the majority of research utilising mouse models to investigate efficacy. 
Mice have similar physiology to humans and many rodent based imaging and detection 




1.11 Methods of drug delivery 
 
Use of targeted delivery mechanisms are not limited to any one organ and have seen wide use 
in a variety of diseases such as cancer therapies129-131, Alzheimer’s disease132, inflammatory 
bowel disease133 and many more. A variety of different methods have been developed for 
targeted delivery of drugs to the kidney for use in several renal diseases. 
Prodrugs, which are metabolised and activated within the targeted region of the body, have 
been developed to target certain reactions in the kidney, such as protein-sugar interactions134, 
135,136 amino acid reactions137 and folate filtering131. 
Nanoparticles are able to have their size, charge, shape and density designed specifically to 
facilitate an exact purpose within the body128. They have been shown to accumulate in 
specific areas of the kidney, including the rat glomerular mesangial cells138 and the mouse 
mesangium139. 
Liposomes, which can be endocytosed into target cells, have been found to be particularly 
effective in in cancer therapy140,141 with some liposome-containing therapies already existing 
in the market128. 
Macromolecular carriers represent the broadest grouping of drug delivery systems, classified 
by their ability to bind to a drug and deliver it to the target region, with no immunogenic 
effect (Figure 1.5)128.  Lysozymes, a low-weight endogenous protein, are particularly popular 
as they offer specific kidney uptake and are easy to conjugate to drugs. Lysozymes have been 
successfully used several times to deliver therapies, with reports showing up to 70x greater 
drug concentrations in targeted cells than the drug itself142,143,144,145. 
Low molecular weight chitosan (LMWC) and polyvinylpyrrolidone (PVP) have both been 
shown to have varying renal targeting ability based on their molecular weights146,147. 
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Several peptide delivery molecules have been developed including TAT148 and Pep-1149, 
which have both recently been used in the development of target cancer therapies150,151. This 
is due to the peptides inherent non-toxicity in the body to efficiently deliver the conjugated 
drug with increased effectiveness over a global treatment approach, although the relatively 
short half-life of peptides decreases the longevity of the treatment and may require more 
frequent treatments compared to other delivery molecules152.  
The galectin-3-avid peptide (C3-G12) has been shown to specifically accumulate in mouse 
kidneys after IV injection153 and has recently been shown by Geng et al., (2012)154 to 
effectively deliver the drug captopril within the kidneys. The group used the green 
fluorescent probe FITC bound to the C3-G12 peptide and showed accumulation of the C3-
C12-FITC conjugate in mouse kidneys. They also conjugated the chronic kidney disease 
(CKD) drug captopril (CAP) and showed that the C3-G12-CAP conjugate accumulated 
within the kidney significantly more than CAP alone. 







Figure 1.5: Macromolecule-drug conjugates (such as C3-G12) free in the blood where they are filtered by the 
kidney and are absorbed by the targeted cells. The conjugate bond is then cleaved, depositing the drug in the 
target while the macromolecular carrier leaves the system. Image from Zhou et al., (2014)128, reproduced 
without modification under Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported. 
 
1.12 Hypotheses 
Approximately 85% of ADPKD patients inherit one non-functioning copy of PKD1 from 
their parents. A prevailing hypothesis suggests that the commencement of cyst formation 
involves the loss of function of the remaining functional PKD1 allele by a “second hit” 
mechanism in somatic cells in the kidney nephron. The PKD1 gene lies in a CpG rich 
region155 with many CpG islands located in the gene itself. We hypothesize that one 
mechanism of generating a “second hit” could be DNA methylation silencing of the second 
PKD1 allele. If this hypothesis is accurate then epigenetic altering therapy could be used to 
target any methylation irregularities found in the cystic cells. This could be tested in a mouse 
by targeted delivery of methylation altering molecules and assessing the effect on renal cyst 
formation. We hypothesise that the mouse Pkd1 methylation landscape may be similar to the 
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human PKD1 gene and that a methylation silencing second hit mechanism may also be 
observed in a mouse model for ADPKD. 
In order to test this hypotheses, we will investigate DNA methylation in the mouse Pkd1 gene 
in both wildtype and Pkd1 heterozygous mice and compare against what has already been 
published in human studies. 
The C3-G12 peptide is one of many targeted delivery molecules currently being researched 
with the intention of efficiently delivering a therapy to the diseased tissue, minimising side-
effects that may follow a whole body treatment. The C3-G12 peptide has been shown to 
accumulate in the kidneys of mice154. To investigate the kidney specificity of a targeted 
peptide for the purpose of future ADPKD therapy delivery in our hands, we will examine the 
bio-distribution of the C3-G12 peptide conjugated to a fluorescent marker Cy3.5. 
 
1.13 Previous work 
 
An investigation of the DNA methylation status in the Pkd1 promotor of wildtype mice and 
the Pkd1 mutant mouse model (del34) was performed in my Postgraduate Diploma of 
Science. 
A 292 bp region in the promotor of the mouse Pkd1 gene was bisulfite treated and cloned 
from kidneys samples derived from five del34 mutant heterozygotes and five wildtype mice 
of ages 13-19 months (details in Appendix 4). Methylated and unmethylated cytosines were 
quantified and compared, showing that the region was completely unmethylated with no 
evidence of any difference between the del34 heterozygote and wildtype Pkd1 promotor 
region. This suggests that the mouse Pkd1 promotor is active in the adult kidney and that the 
Pkd1 gene may be able to be transcribed. 
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A paper by Woo et al., (2014)104 compared the DNA methylation of ADPKD and wildtype 
tissues at two specific regions of the human PKD1 gene. The equivalent promotor region in 
the del34 mouse model was investigated in my Post Graduate Diploma and the equivalent 
mouse gene body region will be investigated in this study, as Woo et al., identified a 
methylation difference in this region. The del34 mouse will be used to identify the 
methylation differences in a mouse model of ADPKD that could later be targeted for the 
development of an ADPKD therapy. 
 
1.14 Aims  
1. To compare DNA methylation in the mouse Pkd1 gene body region in both Pkd1 
heterozygous and wildtype mice, to determine if any methylation differences exist between 
the two that may support an epigenetic “second hit” in ADPKD pathogenesis.  
2. To use reduced representation bisulfite sequencing (RRBS) to extend the limited human 
data available and get a detailed analysis on the human PKD1 methylation landscape and 
compare against published data by Woo et al., (2014)104. 
3. To test the ability for a proposed targeted delivery peptide C3-G12 to localise to the kidney 
in Balb/c mice, by using a conjugated Cy3.5 fluorescent tag. Fluorescent imaging techniques 








Chapter 2: Methods 
2.1 Sources of tissues and DNA 
Previous researchers extracted DNA from the kidney tissue of ten del34156 mice (Qiagen 
QIAamp DNA Mini Kit, ~10 µg yield for each sample). The del34 polycystic kidney disease 
mouse model was generated using site targeted mutagenesis methods, which mutated one 
copy of the Pkd1 gene. The mice develop a small number of cysts in later life that do not 
inhibit kidney function156. Both wildtype and heterozygous mice were used in the analysis. 
Embryonic mouse samples were created by crossing heterozygous del34 mice to create 
homozygous and heterozygous embryos which were isolated and genotyped by past 
researchers at embryonic day 18.5 and stored in -80 °C. 
All solutions used in this study can be found in Appendix 1. 
 
2.2 Analysis of mouse Pkd1 gene body methylation 
2.2.1 DH5α competent bacteria creation 
 
DH5α competent Escherichia coli (E.coli) bacteria were generated using the Zymo “Mix & 
Go E. coli transformation kit & buffer set – Cat. T3001” and snap frozen in a dry ice/ethanol 
bath. They were then stored at -80 °C under the approval number GMO05/UO15 as 




2.2.2 Bisulfite treatment of mouse DNA 
 
Samples were bisulfite treated using the Zymo “EZ DNA Methylation-Gold – Cat. D5005” 
kit on a BioRad DNA Engine Peltier Thermal Cycler with no changes to the provided 
protocol (bisulfite incubation at 64 ºC for 2.5 hours).  Samples were eluted in 10 µl with the 
supplied elution buffer and stored at -20 °C. 
 
2.2.3 Gene body amplification 
 
To compare the mouse Pkd1 methylation landscape to that of human PKD1 samples 
published by Woo et al., (2014)104, the equivalent gene body region (procured from 
Ensembl113 – Appendix 5) in the mouse Pkd1 gene was amplified by primers designed by the 
Zymo website “Bisulfite Primer Seeker”157. This gave a fragment 232 bp long in exon 43. 
This region captured 8 potentially methylated CpG’s but was not defined as a CpG island by 
the “NCBI CpG island strict prediction algorithm”158. 
Exon 43 of the Pkd1 gene bisulfite treated DNA was then amplified using the following PCR 











 Table 2.2: Thermocycler settings for sufficient amplification of the bisulfite treated DNA 
 
 
Samples were then placed at 4 oC temporarily prior to gel electrophoresis. Bisulfite treated 
DNA is less stable than untreated DNA, so long term storage was avoided.  
 
2.2.4 Gel electrophoresis of amplified bisulfite samples 
 
To ensure the correct sized product had been amplified, PCR samples were electrophoresed 
on a 2% agarose gel using the appropriate amounts of 1x Tris-acetate (TAE) buffer and 
agarose powder. The gel running buffer was made up from 1x TAE and 50 µg/mL ethidium 
bromide. 1 µl of Thermo Scientific Loading Dye was used for all wells with 5 µl (1 µg/µl) of 
Invitrogen “1 Kb Plus DNA Ladder” and samples respectively. The gel was run at 100 volts 
Reagent each reaction 
MQH2O 15.20 
10X PCR Buffer 2.00 
50mM MgCl2 (1.0mM final) 0.40 
10mM dNTPs (0.2mM final) 0.40 
10uM PKD1F (0.2uM final) 0.40 
10uM PKD1R (0.2uM final) 0.40 
Platinum Taq polymerase 0.20 
Master Mix volume 19.00 
Sample 1.00 
Total PCR volume 20.00 
Cycle step Temperature Time Cycles 
1 Initial denaturation 95 °C 2 minutes 1 
2 Denaturation 95 oC 30 seconds 
40 3 Annealing 52 oC 30 seconds 
4 Extension 72 oC 30 seconds 
5 Final extension 72 oC 7 minutes 1 
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for 30 minutes and then visualized under UV light on a Bio-Rad XR gel visualizer using the 
Quantity One 4.6.5 Basic software. The amplified samples were confirmed to be of the 
correct size before proceeding to any future steps. 
The PCR fragments were purified using the Invitrogen “Purelink PCR Purification Kit”. The 
final elution volume, which was listed in the manufacturer’s protocol as being 50 µl, was 
changed to 20 µl to ensure a higher concentration of DNA 
A Nanodrop 1000 3.8.1 was used to quantify the DNA using the appropriate elution buffer as 
a blank. 
 
2.2.5 Transformation of bisulfite treated Pkd1 
To create a bacterial library containing unique DNA fragments of the target region, the DNA 
was transformed into competent bacteria. A modified protocol generating higher 
transformation efficiency was determined previously in my Post Graduate Diploma. This 
modified protocol was used to transform the amplified bisulfite converted DNA samples into 
the DH5α bacteria (Table 2.3). 
The Invitrogen “TOPO TA Cloning Kit for Sequencing” was used to create the vector-sample 
constructs. This particular kit used the “TOPO 4.0 vector” (Appendix 2). The listed volumes 
in the supplied protocol were halved with no observed detrimental effect on the experiment.  
The TOPO 4.0 vector contains thymidine overhangs at each end which easily binds to the 
adenosine overlay produced by Taq polymerases. Insertion of a PCR product disrupts the 
lethal lacZα-ccdB genes and allows the bacteria to grow; vector alone will not grow. 
Combined with an ampicillin selection marker, only cells containing the vector+insert are 
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capable of growing on ampicillin media, therefore traditional blue/white colony selection was 
unnecessary. 
Cells with no DNA were used as a negative control, whereas cells transformed with the 
Invitrogen pUC19 vector were used as a positive control. Lysogeny broth (LB) + agarose + 
ampicillin (LBAA) plates were made with Invitrogen LB Agar powder and 25 µl of 100 
mg/ml ampicillin per plate. All steps listed in Table 2.3 were performed on ice. 
 
Table 2.3: The improved method used for the transformation of the bisulfite treated Pkd1 
gene body region into DH5α E. coli cells 
Steps Cell control pUC19 control TOPO reaction/Pkd1 
1 Add 25 µl DH5α cells Add 25 µl DH5α cells Add 25 µl DH5α cells 
2 - Add 1 µl (10 pg) pUC19 vector Add 2 µl of TOPO reaction (2 µl 
PCR product + 0.5 µl salt solution + 
0.5 µl TOPO vector) 
3 - Incubate 5 mins on ice Incubate 5 mins on ice 
4 - Heatshocked at 42 oC for 30 seconds Heatshocked at 42 oC for 30 seconds 
5 - Returned to ice for 2 mins Returned to ice for 2 mins 
6 250 µl SOC added 250 µl SOC added 250 µl SOC added 
7 1 hour in 37 oC shaking incubator 1 hour in 37 oC shaking incubator 1 hour in 37 oC shaking incubator 
8 Pipette 100 µl onto LB and 
LBAA plates 
Pipette 100 µl onto LBAA plates Pipette 100 µl onto LBAA plates 
Adapted in my previous work in my Post Graduate Diploma. 
Transformation mix was spread evenly onto the LBAA plates with a glass pipette and 
spreader. Plates were left upside down for 18 hours in a 37 °C incubator. The transformation 
efficiency was calculated by using the Bioruffo “Online Transformation Efficiency 
Calculator”159. 
29 
2.2.6 Overnight culture of selected colonies 
Bacteria that had successfully transformed with the vector and insert grew overnight on the 
LBAA plates. Individual colonies were picked with autoclaved toothpicks before being 
placed into a 50 ml falcon tube containing 3 ml LB and 3 µl of 100 mg/ml ampicillin.  
Tubes were then placed into a shaking incubator at 37 °C at 200 RPM for ~16 hours. 
 
2.2.7 Plasmid prep of overnight cultures 
To sequence the amplified DNA fragments, the plasmid was isolated from the bacteria using 
the Zymo “Zyppy Plasmid Miniprep Kit – Cat. D4020”. The manufacturer’s instructions for 
this kit did not require samples to be centrifuged to concentrate the bacterial colonies prior to 
lysation of the cells. Due to sporadic insufficient growth of the bacteria overnight and 
subsequent low plasma DNA yields, this centrifugation step was added to the provided 
protocol to improve output DNA concentration. Cultures that were less cloudy, indicating 
less bacterial growth, were spun down using a benchtop centrifuge. The supernatant was 
removed and the cells resuspended in 600 µl of MilliQ water to increase cell concentration 
and therefore output DNA concentration. Additionally to avoid carry over of ethanol and 
other kit residues, a one minute time gap was added between washing steps to allow for 
evaporation. The eluted DNA concentration was measured on a Nanodrop 1000 3.8.1. 
 
2.2.8 Sequencing of plasmid preps 
Isolated DNA was prepared for sequencing using the University of Otago “Genetics Analysis 
Service” guidelines which required 150-200 ng of plasmid DNA, 3.2 pmol of primer 
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combined with a total volume of 5 µl. The primer used for sequencing was the TOPO 4.0 
M13 Reverse primer (Appendix 3), as supplied by the Invitrogen “TOPO TA Cloning Kit” 
used in Step 2.2.5. This primer binds outside of the vector DNA insert region, allowing the 
sequencing of the inserted DNA. 
 
2.2.9 Analysis of methylation data 
The returned sequences were visualised and checked for quality in the program Geneious 
8.1.7 (Restricted Version). Vector DNA bases were trimmed from each end of the insert 
sequence to leave the target DNA. Methylograms were produced by using the BiQ-Analyser 
2.0160 software. The BiQ-Analyser automatically removed poor sequences below an 80% 
sequence homology threshold, as well as the alignment of remaining sequences and relevant 
CpG’s against a reference wildtype Pkd1 sequence. The reference Pkd1 gene was acquired 
from Ensembl Genome Browser113. 
 
2.2.10 Statistical analysis 
 
Data was arranged into two groups at each CpG, separating the wildtype and del34 sequences 
for both the promotor (data obtained previously in my Post Graduate Diploma) and gene 
body regions. Each CpG within those regions were then tested using a Mann-Whitney U-test 
to identify if there was any significant difference in methylation between samples that were 
wildtype and those that were from del34 kidneys. This test was chosen because the datasets 
were not normally distributed, and therefore a t-test was inappropriate. 
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2.3 Creation of cDNA 
To examine the correlation between methylation status and Pkd1 gene expression, RT-qPCR 
was performed on mouse RNA samples. 
RNA was extracted from 13 frozen mouse kidneys, using the Qiagen “RNeasy Mini Kit”. 
The protocol was followed as provided by the kit. All ten mouse kidney samples used for the 
cloning based methylation study were processed, with an additional three embryonic mouse 
samples (wildtype, heterozygous and homozygous for the Pkd1 disruption). Extracted RNA 
from each mouse kidney was then converted to cDNA using the Applied Biosystems “High-
Capacity cDNA Reverse Transcription Kit”. The lowest concentration of RNA obtained was 
21.6 ng/µl, and as the cDNA reaction requires 10 µl input, 216 ng of RNA was converted to 
cDNA for each sample. A control sample was also included in each conversion reaction that 
contained all reverse transcriptase kit reagents minus any RNA. 
 
2.4 RT-qPCR of samples 
The relative expression of Pkd1 in the appropriate sample was measured by performing a RT-
qPCR analysis. All cycle threshold (CT) values for RT-qPCR and standard curves were 
generated on a Roche Light Cycler 480 II using the Takara “SYBR Premix Ex Taq (Tli 
RNaseH Plus)” enzyme. Hypoxanthine-guanine phosphoribosyltransferase (HPRT) and 
glyceraldehyde-3-phosphate dehydrogenase) GAPDH were chosen to be suitable 
housekeeping genes for the mouse samples and had previously been assessed for suitability in 
cystic samples. Initially, RT-qPCR primers obtained from published literature for the target 
Pkd1 gene in mouse, gave two bands. Working primers were designed from the NCBI 
Primer-BLAST tool161. Primers are listed in Appendix 3. 
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Primers used for RT-qPCR are required to amplify the cDNA in a linear pattern to be able to 
directly compare between samples. To determine suitability for RT-qPCR analysis, an 
amplification efficiency standard curve was performed. 
A cDNA sample was diluted seven times in 1:4 increments to give a dilution range that was 
then run on the Roche Lightcycler 480 II (using supplied software Lightcycler 1.5.1) with 
target and housekeeping gene primer sets. The protocol supplied by the SYBR kit was 
modified to use less reagents with no detrimental effects on results. CT values were generated 
from each well by the “absolute quantification second derivative max” protocol. Standard 
curves were plotted using GraphPad Prism 6.07 (Demo). 
 
Table 2.4: The SYBR based RT-qPCR protocol followed to generate second derivative 







Following the confirmation that the Pkd1 primers were suitable, a RT-qPCR was performed 
with undiluted primers following the protocol listed in Table 2.4. 
 
Per well 
SYBR Premix Ex Taq (2x) 5 
F-Primer (5 µM) 0.2 
R-Primer (5 µM) 0.2 




Each sample was performed in triplicate, for each primer set (a total of nine reactions per 
sample per plate). All samples were repeated a second time as a technical replicate. Controls 
were included on each plate, with “no RNA or cDNA” triplicates for each primer and three 
reverse transcribed controls as noted in Section 2.4. 
2.5 Genotyping of qPCR results and re-analysis 
Following the RT-qPCR analysis, the wildtype mouse sample 1314 revealed Pkd1 expression 
levels similar to that of the heterozygote samples (Section 3.2). To further investigate this, a 
genotyping PCR reaction was performed with one negative and one positive control. Primers 
listed in Appendix 3. 
Table 2.5: Genotyping PCR performed to identify the Pkd1 genotype of the 1314 sample.  
Reagent each reaction 
MQH2O 14.20 
10X PCR Buffer 2.00 
50mM MgCl2 (1.0mM final) 0.40 
10mM dNTPs (0.2mM final) 0.40 
DMSO 1.00 
10uM NeoFII F (0.2uM final) 0.40 
10uM Mr50 R (0.2uM final) 0.40 
Platinum Taq polymerase 0.20 
Master Mix volume 19.00 
Sample 1.00 
Total PCR volume 20.00 
 
The samples were run on a 2% agarose electrophoresis gel following the same protocol listed 
in section 2.2.4 and viewed on the Bio-Rad XR gel visualizer. The 1314 sample was then 




2.6 H&E staining of mouse samples 
To analyse the quantity and morphology of the cysts in the mouse samples, the ten mouse 
kidneys from which the DNA was extracted (Section 2.2) were embedded in paraffin, 
sectioned and hematoxylin and eosin (H&E) stained by the Otago Histology Services Unit. 
Sectioned kidneys were imaged under an Olympus DP80 microscope and findings confirmed 
by a pathologist in the department.  
 
2.7 Human tissue ethics approval 
 
Three wildtype human kidney tissues were obtained from the Christchurch Tissue Bank162 
following ethics approval by the “Otago Human Ethics Committee” H15/110. Tissue was 
taken during surgical procedures to remove renal tumours. The tissue taken was cortical and 
sampled as far from tumours as possible. An additional two human ADPKD tissue samples 
were used from donated tissue as approved by the Otago Human Ethics Committee H15/110.  
 
2.8 Genome-wide methylation analysis 
To gain a representative look at DNA methylation across the genome of the human ADPKD 
derived kidney tissue, reduced representation bisulfite sequencing (RRBS) was used to 
perform a genome wide methylation analysis on two human ADPKD kidney tissue samples, 
and three human wildtype tissue samples.  
RRBS is performed by digesting the DNA samples with the MspI restriction enzyme, which 
breaks the DNA into fragments. It is then size selected to remove small, difficult to align 
fragments, and large fragments which are often CpG poor125, to collect a representative 
sample of the entire genome that is enriched for CpG islands.    
35 
The RRBS protocol is one heavily modified by members of our laboratory including Dr. 
Aniruddha Chatterjee and Dr. Euan Rodger. The entire methodology will not be described. 
Instead key areas of the process will be highlighted. The full process is detailed in the 
publication “Technical Considerations for Reduced Representation Bisulfite Sequencing with 
Multiplexed Libraries”163. 
 
2.8.1 DNA extraction for RRBS 
DNA was extracted from the kidney tissues by the Qiagen “QIAamp DNA Mini Kit”, using 
the “mortar and pestle” method, where frozen sections of tissue were sliced on dry ice, and 
then ground in lysis buffer with a plastic pestle. Treatment with Proteinase K was performed 
for 16 hours overnight at 56 ºC, as opposed to the recommended 3 hours, due to the 
requirement for increased DNA yields.  The kit protocol recommended 25 mg of tissue with 
an output of 5-30 µg of DNA. Between 18-25 mg of tissue was used for each sample, 
resulting in varying DNA yields between 2-15 µg.  DNA was checked for quality on a 
Nanodrop 1000 3.8.1 and quantity was confirmed on a Qubit 2.0 Fluorometer DNA 
quantification system. 
 
2.8.2 MspI digestion and end repair 
Samples then underwent MspI digestion, where the MspI enzyme slices DNA between the 
two C’s of a CCGG motif and fragments the DNA. Samples were digested overnight (16 
hours) at 37 °C on the BioRad DNA Engine Peltier Thermal Cycler to ensure full digestion. 
The samples were then purified using the Qiagen QiaQuick PCR Purification Kit. 
The base overhang left by the MspI enzyme cuts was then repaired by Nano End Repair Mix 
2 (from the Illumina TruSeq Nano DNA LT Library Prep Kit). The samples were purified 
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again using the Qiagen MinElute PCR Purification Kit, to produce more concentrated DNA. 
 
2.8.3 Adenylation and sequencing adapter binding 
The 3’ end of the sample fragments were then adenylated prior to sequence adapter binding. 
Unique DNA sequencing adapters were ligated onto the adenylated 3’ ends of the sample 
fragments to allow multiplex sequencing. Adapter combinations were checked against 
published Illumina documentation to ensure no incompatibility issues, where adapters are 
able to bind to each other and may impede the reaction. 
 
Table 2.6: The Illumina DNA sequencing adapters used for each sample. 
Sample Library Adapter 
ADPKD Kidney 1 2 
ADPKD Kidney 2 4 
Wildtype 1 5 
Wildtype 2 6 
Wildtype 3 7 
. 
The samples were purified again using the same Qiagen MinElute kit used above. 
 
2.8.4 First size selection 
To select the representative subset of CpGs to analyse, the samples were run on a 3% Lonza 
“NuSieve GTG Agarose Gel” and the gel area between 150 and 325 bp bands (adapter size 
included) of a 25 bp DNA ladder was isolated for each sample. 
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It was vital the NuSieve gel was prepared carefully. The mixture was heated at 50% power in 
a microwave several times until the liquid gel was completely clear. The gel was poured and 
then left to set at room temperature for one hour. Seven µl (1 µg/µl) of Invitrogen 25 bp DNA 
ladder was used in the first lane for accurate size selection. Three microlitres of Thermo 
Scientific Loading Dye was added to each sample (~ 20 µL total) and then the entire sample 
was run in a lane on the gel with a lane left between each sample to ensure no contamination 
between each sample. The gel was then loaded and run with fresh 0.5x TAE buffer at 50 V 
for 90 minutes. 
The electrophoresed gel was placed on a flat, sterile tissue culture flat disposable flask. The 
ladder lane was sliced off with a thoroughly cleaned knife and imaged under UV in the Bio-
Rad XR gel visualizer. The 150 and 325 bp marks were measured with a ruler and distance 
from the bottom of the gel was noted. The ladder containing gel lane was returned to the rest 
of the gel. Each lane was cut from the gel and separated, thoroughly cleaning the knife after 
each cut. The measured 150 and 325 bp were aligned with each sample lane and the area 
between the two bands removed as illustrated by Figure 2.1.  
 









Figure 2.1: Diagram of the gel extraction method used for RRBS. Only the 325 and 150 bp bands of the DNA 
ladder are shown. The DNA ladder bands were measured under UV light then placed back alongside the gel. 
Blue dashed lines indicate where the gel was cut with a knife based on the measurements. Blue rectangles 
indicates the area removed for further processing. 
Each sample’s gel fragment was placed into individual 2 mL Eppendorf tubes and weighed. 
The DNA was then extracted using the Qiagen QIAquick Gel Extraction Kit. 
 
2.8.5 Bisulfite conversion of samples 
The size selected DNA was then bisulfite treated using the Zymo EZ DNA Methylation Kit 
to convert any unmethylated cytosines into uracil. The CT conversion reagent provided by 
the kit was used fresh due to increased risk of conversion failure by repeated freeze-thawing. 
The conversion was run for 18 hours at 50 °C on the BioRad DNA Engine Peltier Thermal 
Cycler, to ensure complete conversion. 
 
2.8.6 PCR amplification 
For library preparation, the samples were amplified by PCR. The number of cycles that the 
samples underwent was important due to the increasing risk of point mutations or fragment 
biases125 with each additional cycle of amplification. Samples were amplified just enough to 
produce sufficient yields of DNA Library. To determine the correct number of cycles, a small 
amount of bisulfite converted sample underwent two semi-quantitative PCR reactions for 15 
and 20 cycles. The PCR products were then electrophoresed on a NuSieve gel prepared as 
previously described in the size selection step (4.2.4). The number of cycles required for 
large-scale amplification of each individual sample was then selected based on the intensity 
of the amplified product after visualisation of the gel on the Bio-Rad XR gel visualizer 
(judged by Doctors Chatterjee and Rodger, who designed the protocol). 
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Each of the samples were amplified in a large-scale PCR reaction, using the amount of cycles 
(15-20) previously determined in the semi-quantitative PCR. This was unique to each sample 
so therefore five separate PCR reactions were set up to run concurrently. After amplification, 
the samples were purified using the Qiagen MinElute Kit used previously.  
 
2.8.7 Second size selection 
The amplified samples were run on a NuSieve gel which was prepared and size selected 
exactly as previously described in the first size selection (Section 2.8.4). This additional size 
selection step ensured that the final library preps contained no DNA fragments larger or 
smaller than the selected 150-325 bp. Fragments outside of this region may have been missed 
during the first round of size selection or introduced during subsequent PCR steps by adapter 
and primer dimers. 
The isolated gel fragments were weighed and then gel extracted using the Qiagen MinElute 
Gel Extraction Kit eluted in a final volume of 20 µL. One microliter was then used to 
determine the concentration by Qubit Fluorometer, and another one microliter used for the 
Bioanalyser analysis carried out by New Zealand Genomics Limited (NZGL).  
Once the Bioanalyser data was returned, samples were diluted to 10 nM in 25 µL and 
submitted to NZGL for sequencing on the Illumina HiSeq 1x100 bp Sr V4 platform.  
 
2.8.8 Quality control  
Sequenced libraries were processed by NZGL and assessed for quality control by using the 
program FastQC164 (Version 0.11.3). FastQC generates a series of quality control graphs 
from raw sequence including sequence quality scores (Figure 5.4) and individual base 
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probability (Figure 5.5). The Phred quality score165,166 is the logarithmic likelihood of an 
incorrect base call at any given base and is used as a measure for sequencing. This is plotted 
as a mean, maximum and minimum Phred score at each base of all the reads for a given 
sample. Good quality sequenced libraries are those that show high Phred score (>30), 
markers of complete bisulfite sequencing (low cytosine content) and complete MspI digestion 
(Figure 5.5). 
 
Table 2.7: Phred scores indicate sequencing quality of high-throughput data 








2.8.9 Clean-up and alignment 
Before alignment and analysis, the sequences must be prepared and ‘cleaned’ of poor quality 
reads and adapters removed. Due to the high quality of the sequences, the script only needed 
adapter trimming using the script titled “cleanadapters” 184. 
The sequences were aligned using the program Bismark167 (V 0.14.4) which utilises the 
Bowtie168 fragment aligner. Bismark maps all reads against all four bisulfite conversions, 





2.8.10 Visualisation of the sequences 
To visualise the methylation landscape of the aligned sequences, the tool Integrative 
Genomic Viewer169 (IGV - V 2.3) was used. IGV supports data files that contain information 
at each chromosome, and compares them to a reference genome. Chromosomal locations and 
gene names can be searched to visualise the coverage and depth of reads at any given location 
on the genome. 
 
2.9 Creation of peptide-fluorescent molecule conjugate 
 
To detect the bio-distribution of the C3-G12 peptide within the mouse organs the C3-G12 
peptide was synthesised and conjugated to a Cy3.5 fluorescent marker (GE Healthcare Life 
Sciences Cy3.5 NHS Ester) by our collaborators (Dr Sarojini, School of Chemical Sciences, 
The University of Auckland). 
Previous papers had used FITC as a marker for this peptide, but we chose to use Cy3.5 as it 
fluoresced at the red end of the spectrum with an absorbance at 590 nm and emission at 620 
nm, where there is little background fluorescence in mouse kidneys. This was important as 
we had planned to use the FX-Pro in vivo small animal imager, which is more sensitive to 
background fluorescence in the shorter wavelengths. 




2.10 Comparative fluorescence 
As preliminary experiments revealed that the C3-G12-Cy3.5 conjugate and the Cy3.5 free 
dye did not fluoresce with equal intensity at the same concentration, the fluorescence had to 
be normalised so that the concentration was adjusted in order that equal volumes of solution 
produced equal levels of fluorescence under the microscope. A standard curve was created 
with 1000, 800, 600, 400 and 200 pmol of free dye placed in wells of a Biotek Synergy 2 
plate reader (using Gen 5 1.11 software) and compared against 1000 and 100 pmol quantities 
of the peptide-dye conjugate. Additional 200, 150 and 100 pmol dilutions were made and 
analysed after initial measurements were higher than expected. Multiple replicates were 
made. GraphPad Prism 6 Demo (V 6.07) was used to generate the standard curves. 
 
 
2.11 Injection of mice and timepoints 
Balb/c (~11 months of age) mice were injected by tail-vein IV injection with 50 µl of one of 
three different solutions: 
- Vehicle - 10 µl DMSO made up to 50 µl with normal saline (NS) 
- Cy3.5 - 1 nmol suspended in 10 µl DMSO made up to 50 µl with NS 
- C3-G12-Cy3.5 - 10 nmol suspended in 10 µl DMSO made up to 50 µl with NS 
Mice were culled at three time points after injection of one of the solutions: 
- 3 minutes - three mice for each solution 
- 15 minutes - two mice with Cy3.5 and two with C3-G12-Cy3.5 
- 30 minutes - two mice with Cy3.5 and two with C3-G12-Cy3.5 
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2.12 Fluorescence of mice organs 
The kidneys, liver, heart, spleen and lung were dissected from the mice and viewed 
individually under a Leica M205 FA (LAS V4.4 software) using the dsRED filter. Exposure 
settings were normalised based on background fluorescence of free dye controls, so that the 
free dye samples were barely visible under imaging. 
 
Table 2.8: Microscope settings used for all images of mouse organs  
Exposure 32.8 s 




The fluorescence was measured by the ImageJ (V 1.50b) software and quantified as “Mean 









Chapter 3: Mouse Pkd1 DNA methylation analysis 
3.1 Analysis of mouse Pkd1 DNA methylation 
3.1.1 PCR amplification and yield 
 
DNA from five mice previously genotyped as heterozygous for the del34 Pkd1 disruption and 
five wildtype mice of similar age were bisulfite treated, and a 232 bp region of exon 43 in the 
Pkd1 gene body was amplified by PCR (Sections 2.2.2 and 2.2.3). 
The amplified DNA was electrophoresed on an agarose gel (as described in Section 2.2.4). 
The size of the fragment was compared against the 1 kb+ DNA ladder to ensure that the 
correctly sized target fragment (232 bp long in exon 43 – Appendix 5) had been amplified, 
and that the PCR had been successful. 
 
 
Figure 3.1: Gel electrophoresis of Pkd1 PCR products of bisulfite treated mouse DNA. The visualised gel 
shows a single band for each sample at the expected size compared to the Invitrogen “1 Kb Plus DNA Ladder”. 
The band intensity suggested good amplification. 
 
~232 bp 






The amplified PCR products only showed one band at the expected size (232 bp), therefore 
gel extraction techniques were not used and PCR purification using the “Purelink PCR 
Purification Kit” was sufficient. Eluted DNA had concentrations between 6-10 ng/µl. The 
PCR fragment was directly sequenced to ensure that it was the correct target region of 
exon43 in Pkd1. 
 
3.1.2 Transformation of Pkd1 inserts 
 
To create a bacterial library of the bisulfite treated PCR products, the purified fragments were 
TOPO cloned and transformed into DH5α E. coli bacteria using the Thermo Fisher “TOPO 
4.0” vector as outlined in Section 2.2.5. For each transformation, two sets of control reactions 
were used, one containing DH5α only, to confirm bacterial growth on LB (Lysogeny broth) 
agar and not on LB agar plus ampicillin (LBAA) plates. A second transformation using 
pUC19 was used as a positive control. The quantity of vector and fragment containing 
successful transformations varied with an approximate pUC19 transformation efficiency of 
1.4 x 107 transformants per µg of DNA with ~50 colonies per plate.  
 
3.1.3 Plasmid preparation and sequencing 
 
Overnight cultures of single bacterial colonies were grown overnight. Plasmid DNA was 
prepared from these cultures, producing concentrations of 50-150 ng/µl of DNA, utilising the 
improved methodology described in Section 2.2.5. 
Isolated plasmids were sequenced with the M13 reverse sequencing primer (Appendix 3) 
supplied in the TOPO 4.0 kit. High data quality (80%+ sequence identity with the reference 
sequence) was required in the various analysis software programmes described in section 
2.2.9.  
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3.1.4 Pkd1 Methylogram data 
 
In order to examine the pattern of methylation for each genotype, sequences were aligned by 
BiQ software160 (Section 2.2.9) and methylated CpGs were counted against a completely 
unmethylated reference sequence supplied from Ensembl (release 83113).  “Not present” 
indicates that the sequence quality was insufficient to properly determine methylation status 
at that CpG. This occurred more frequently in the first four CpGs as this was often at the 3’ 




Figure 3.2: Methylograms illustrating the methylation of a 232 bp region of the mouse Pkd1 gene body in exon 
43. The eight CpGs that are within the cloned region are listed with the corresponding quantity of methylated 
and unmethylated CpGs at that position for del34 heterozygous samples (A) and wildtype (B). Values for 





These results show that seven of the eight CpG’s in the 232 bp region of exon 43 of the 
mouse Pkd1 gene body are methylated in both heterozygous and wildtype samples with a 
very small number of non-methylated sequences. One CpG is completely unmethylated in 
both heterozygous and wildtype samples. Statistical analysis was performed (section 3.4.3) to 
identify any significant difference between the Pkd1 del34 heterozygous and wildtype 
samples at each CpG and showed no significant difference at any CpG. 
Additional sequences for a 292 bp fragment in the promotor region (33 CpGs) of the mouse 
Pkd1 gene (Appendix 4) were obtained during the course of this study and were added to 
those obtained during my Post Graduate Diploma research project, using identical methods 
described in “Chapter 2 - 2.2 Analysis of the mouse Pkd1 gene”. New methylograms were 











Figure 3.3: Methylograms illustrating the methylation of a 292 bp region of the mouse Pkd1 gene promotor. 
The 33 CpGs that are within the cloned region are listed with the corresponding quantity of methylated and 
unmethylated CpGs at that position for heterozygous samples (A) and wildtype (B). Values for “unmethylated”, 





These results showed extensive hypomethylation in 32 of the 33 CpGs in this promotor 
region of the mouse Pkd1 gene, in both heterozygous and wildtype samples. Statistical 
analysis was unable to be performed as the majority of CpG’s were exclusively 
hypomethylated in both datasets and showed no difference.   
 
3.2 Pkd1 expression data 
To examine the correlation between the Pkd1 methylation data and Pkd1 gene expression, 
qPCR analysis was performed on 13 mouse kidney samples, five heterozygous for Pkd1 and 
another five wildtype samples that were used for the methylation analysis. Three additional 
embryonic samples (wildtype, heterozygous and homozygous) were included as controls, as 
high expression of Pkd1 is observed during development. Target primers for the Pkd1 gene 
were designed and validated prior to RT-qPCR analysis (Section 2.4, and below). 
 
3.2.1 Primer amplification efficiency 
The primer amplification efficiency for the mouse Pkd1 target gene was plotted in a standard 
curve. Three genes were used, target gene Pkd1 and housekeeping genes Hypoxanthine-
guanine phosphoribosyltransferase (HPRT) and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH). The ideal RT-qPCR primer would have an amplification factor of 2, where each 
subsequent amplification cycle produces exactly double the RT-qPCR product of the 
previous cycle, and an efficiency of 100%, where each cycle amplifies 100% of the last 
cycle’s RT-qPCR product. 
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Amplification efficiency and amplification factor for the Pkd1 primer (Appendix 3) was 
generated by using the ThermoFisher Scientific qPCR Efficiency Calculator170. RT-qPCR 
optimisation was confirmed by comparing the R2 value of the standard curve slope for each 
primer against the optimal value of >0.980 as defined by “Bio-Rad Real-Time PCR 
Applications Guide”171. 
The Pkd1 primer had an amplification factor of 1.95 and efficiency of 95.27%, which is 
extremely close to the ideal amplification of 2 and efficiency of 100% and confirms that the 
primer is suitable for RT-qPCR analysis. The Pkd1, HPRT and GAPDH standard curve R2 
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Figure 3.4: Standard curves for RT-qPCR of mouse Pkd1, GAPDH and HPRT. The Pkd1 primer efficiency was 
calculated as 95.27% with an amplification factor of 1.95, based on standard curve results (A). Housekeeping 
genes GAPDH and HPRT showed R2 values above the recommended value of 0.980 for optimised RT-qPCR (B, 
C). Dilutions of a cDNA sample were made in 1:4 increments up until cycle threshold (CT) readings exceeded 
the detectable quantity of 35. “0” dilution is an undiluted sample. 
 
3.2.2 Pkd1 expression of wildtype, heterozygous and embryonic samples 
After the RT-qPCR reaction was optimised, the relative gene expression of the ten wildtype 
or del34 heterozygous mouse samples used in Section 2.2, and three embryonic (wildtype, 
heterozygous and homozygous for the del34 Pkd1 gene disruption) were measured.   
Pkd1 expression was normalised against the HPRT and GAPDH housekeeping genes 
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Figure 3.5: Consistent expression of the GAPDH and HPRT housekeeping genes. WT = Wildtype, HET = del34 
heterozygous and E-HOM, E-WT and E-HET = embryonic homozygous, wildtype and heterozygous for the 





The Pkd1 gene expression results (Figure 3.5) showed lower expression in the wildtype 











expression was approximately three times the expression of the non-embryonic del34 
heterozygous samples and approximately six times the non-embryonic wildtype samples. The 
embryonic wildtype and heterozygous Pkd1 expression level was similar to that of the non-
embryonic heterozygous samples. 
The expression data showed high levels of Pkd1 expression for wildtype sample 1314, when 
compared with the other wildtype samples. Sample 1314 had been previously genotyped as a 
wildtype mouse (in provided documentation). To investigate this further, we undertook a 
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Figure 3.6: Relative quantity of Pkd1 expression in 13 mouse samples. Two technical replicates were 
performed with error bars representing the standard error of mean. Quantity was normalised against two 
housekeeping genes, which showed consistent expression across all samples. Samples are numbered according 
to their mouse number (age ~17 months) with the last three consisting of embryonic samples (E18.5) that were 
homozygous (E-HOM), wildtype (E-WT) and heterozygous (E-HET) for the Pkd1 mutation respectively. 
Sample 1314 had been genotyped as wildtype in provided documentation, but showed a Pkd1 expression level 
consistent with heterozygous samples. Re-genotyping of this sample was then performed. 
 
3.3 Genotyping sample 1314 
 
Mouse sample 1314 (Appendix 4) was originally documented as a wildtype sample and was 
initially analysed as such. The results of the qPCR experiment (Figure 3.6) suggested that the 
sample had a Pkd1 expression pattern more similar to a heterozygote sample rather than a 
wildtype. To confirm the sample’s genotype a genotyping PCR was performed. Samples 
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heterozygous for the Pkd1 del34 disruption produce a single band of ~400 bp on a 2% 
agarose electrophoresis gel. A positive, negative and water control was used. 
Figure 3.7 shows that the sample 1314 was in fact heterozygous for the Pkd1 del34 
disruption. The methylogram and statistical data were reanalysed, taking this into account 
(see Figures 3.8, 3.9 and Table 3.1). 
 
 
Figure 3.7: Genotyping PCR of sample 1314. Ladder = 1 kb+ DNA ladder. The 1314 sample showed a single 
band at approximately 400 bp. This indicates that the sample was heterozygous, and is confirmed by the positive 
(heterozygous for the Pkd1 disruption) and negative (wildtype) controls. The negative control for this PCR 
reaction often shows bands of other sizes. 
 
3.4 Reanalysed methylation, expression and statistical data 
 
The qPCR expression data, and the methylation data obtained from the Pkd1 gene 
methylation study, was re-analysed, with the sample 1314 re-classified as a Pkd1 
heterozygote. The updated methylation data has been presented as “lollipop plots” (Figure 







3.8). There was no change in the outcome of the analysis. 
 
3.4.1 Methylation lollipops 
 
The raw methylogram data was plotted in a “lollipop plot” (Figure 3.8) to compare the level 














Figure 3.8: Lollipop comparison plot of mouse Pkd1 promotor and gene body methylation. Each CpG in the 
gene body (A, 1-8) and promotor (B, 1-32) regions are represented by a lollipop. The green line represents the 
division between Pkd1 del34 heterozygous samples (top) and wildtype samples (bottom). The colour indicates 
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3.4.2 Averaged Pkd1 expression 
 
To illustrate the trend of lower wildtype Pkd1 gene expression versus the higher Pkd1 del34 
heterozygote expression of the mouse Pkd1 gene, normalised relative quantity qPCR data 
was averaged and graphed (Figure 3.9), using the new classification for sample 1314. 
 
Figure 3.9: Average Pkd1 expression of wildtype and del34 heterozygous mouse samples. Wildtype Pkd1 
expression was approximately one third of the del34 heterozygous samples. Sample 1314 was included in del34 
heterozygous samples after evidence for heterozygosity. Error bars represent the standard deviation.  
 
3.4.3 Statistical data 
 
Sequenced bisulfite-treated clones for Pkd1 exon 43 were aligned and the methylation at each 
individual CpG was compared directly between the wildtype and del34 heterozygous datasets 
using the Mann-Whitney U-test (Table 3.1). The null hypothesis was defined as there being 




Table 3.1: Mann-Whitney U-test at each CpG of a 232 bp region of mouse Pkd1 exon 43 
  CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 
Z-score 0.0046 0.2308 -0.1656 0.4849 -0.888 0.0388 -0.591 0.3182 
P-value 1 0.8181 0.86502 0.63122 0.37346 0.9681 0.5552 0.74896 
U-
value 
821.5 744 1069 1111.5 1219 1350.5 1265 1278.5 
 
The p-values shown in Table 3.1 (>0.05) all confirm the null hypothesis and all U-values 
confirm the distribution is approximately normal. Therefore the Z-value listed can be 
accepted as accurate, showing therefore there is no significant difference in the methylation 
status of the gene body in mouse kidney samples between wildtype or del34 heterozygous 
samples.  
The re-analysed promotor region of Pkd1 was almost exclusively unmethylated and statistical 
tests were not able to be used. 
 
3.5 Histology of mouse kidneys 
 
Del34 mouse models produce few cysts with limited renal impairment and potentially 
methylation changes may only be found in cystic tissue. This may explain why no significant 
differences were found in methylation between wildtype and heterozygous mouse Pkd1 gene 
body samples. To examine the density of cysts in our samples, all ten corresponding mouse 
kidney tissues (section 2.2), which had been fixed in 10% neutral buffered formalin (NBF) 
and stored in 70% ethanol (for approximately seven years), were embedded, sectioned and 
hematoxylin and eosin (H&E) stained. Samples were examined for tissue integrity, quality 
and the presence of cysts (Figure 3.10) and one H&E section per kidney was examined from 
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the midsagittal plane of the kidney. All samples appeared to be in good condition with very 
little evidence of cystic tissue. Only one sample (heterozygous 1332) exhibited an obvious 
cyst; this was confirmed by a third-party pathologist in the department. Potentially, the lack 
of cysts identified in the mouse kidney tissue may explain the lack of methylation differences 
seen. As only one section was made from each kidney, it is likely that further cysts exist 
















Figure 3.10: H&E staining of mouse kidney tissue used in analysis. Ten samples were imaged and checked for 
tissue integrity and evidence for cysts: Wildtype cortex (A) and medulla (B) and del34 heterozygous cortex (C) 
and medulla (D). None of these images showed any cystic structures. A cyst was identified in the mouse kidney 
sample 1332 (E, del34 heterozygous). F - A magnification of the boxed region in E. Characteristic features such 
as the “Hob nailing” of epithelial nuclei extending into the centre (1), flattened epithelial cells (2) and cellular 
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3.6 Mouse and Human PKD1 DNA methylation landscape 
The mouse Pkd1 and human PKD1 genes were compared using sequence data available from 
the NCBI gene database158, as observed differences between the human and rodent 
methylation data and presentation of ADPKD may be due to differences between the human 
PKD1 and mouse Pkd1 gene. The mouse Pkd1 shares 79% predicted protein homology with 
human PKD1172. The human PKD1 contains a large duplicated region in the 5’ end that has 
~97 % similarity to six pseudogenes on chromosome 16 (Figure 3.11)173. The mouse genome 
does not contain any duplicated pseudogenes of Pkd1. 
The predicted CpG islands across the two genes, as defined by the “NCBI CpG island strict 
prediction algorithm”158, showed some differences. Notably, fewer and smaller CpG islands 
are observed in the mouse Pkd1 gene. 
The equivalent mouse promotor and exon 43 gene body regions of the human gene that were 
examined in Woo et al., (2014)104 were investigated in this current study. The mouse 
promotor region and its equivalent human promotor region both lie in CpG rich areas. The 
mouse equivalent region to human exon 43 lies close to, but does not contain a CpG island. 







Figure 3.11: A comparison of the PKD1 and Pkd1 gene landscapes between human and mouse. The human 
duplicated region is highlighted in red26. Orange bars represent exons, green bars represent CpG islands. The 













Human Duplicated Pseudogene Region – Six copies located at 16p13.1 with ~97% identity 
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Chapter 4: Discussion of mouse Pkd1 methylation 
4.1 Pkd1 gene body methylation 
 
This study examined DNA methylation in two regions of the mouse Pkd1 gene, a 292 bp 
region in the gene promotor and a 232 bp region of the exon 43 (gene body) in Pkd1. We 
identified no difference in the promotor region and found no significant difference in the 
methylation of the gene body between wildtype and del34 heterozygous mouse kidneys. 
A paper by Woo et al., 2014104 previously identified an increase in gene body methylation, 
which correlated with a decrease in PKD1 expression in human patients with ADPKD. They 
found no difference in promotor methylation but did observe an increase in PKD1 gene body 
methylation, particularly in exon 43. A change in methylation could serve as a “second hit” 
for ADPKD pathogenesis, where the first PKD1 allele is knocked-out by an inherited 
mutation and the second is silenced by changes in DNA methylation. Our aim was to 
investigate if a similar difference might occur in the heterozygous del34 mouse model that 
develops cysts in late onset in a similar manner to human ADPKD.  
We began by investigating the equivalent gene body region in the mouse Pkd1 gene to that 
analysed in human PKD1. This sequence only contained eight CpGs and wasn’t considered a 
CpG island based on the NCBI Strict algorithm. We identified that the gene body region for 
both wildtype and del34 heterozygous samples was almost entirely hypermethylated, with a 
Mann-Whitney U-test on each CpG confirming no significant difference between samples at 
any of the CpGs. Both groups contained a single CpG that was unmethylated, which may 
indicate the border between distinct hypomethylated and hypermethylated regions in the 
mouse gene body, as was seen in several regions of the human PKD1 gene in our data in both 
ADPKD and wildtype samples. Techniques such as genome-wide and reduced representation 
bisulfite sequencing could be used to investigate the DNA methylation status of the entire 
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methylation landscape or specific CpG islands across the Pkd1 gene to determine if any 
methylation differences may be located elsewhere that may reflect the published human data. 
A technical issue that hampered this study was that the amount of high quality sequences that 
exceeded the required quality control checks set by the BiQ methylogram software were 
often few. The protocol was altered multiple times with the intent on improving sequence 
quality and efficiency of the process, although transformation efficiency was improved, 
sequence quality remained low with the majority of sequences not reaching the 80% 
reference sequence identity set by BiQ. This may be due to residual reagents in the eluted 
DNA, although the methods (section 2.2.7) were altered to reduce this possibility. 
The Pkd1 mouse equivalent region of the human PKD1 promotor examined in Woo et al., 
2014104 was investigated during my Post Graduate Diploma and was re-analysed with 
additional sequences acquired during this Masters project. All 33 CpG’s within this promotor 
region were hypomethylated in both wildtype and del34 heterozygous samples. Current 
literature92,96 on DNA methylation suggests that a hypomethylated promotor region and 
hypermethylation in the gene body is what we would expect for a transcriptionally active 
gene88,94-96. It has been suggested that gene body methylation can suppress transcriptional 
noise that may disrupt regular gene expression, as well as regulating enhancer and silencer 
sequences. A hypomethylated promotor region allows the binding of transcription factors to 
the DNA and subsequently the initiation of gene expression. Woo et al., 2014104 also found 
that the human PKD1 promotor was hypomethylated and the gene body was 
hypermethylated, which suggests that the gene is active in adult tissue, as we have observed 
for the Pkd1 gene in mice. The Woo group however identified an increase in methylation in 
the PKD1 gene body. This was not able to be observed in our studies, as all sites investigated 
showed no significant difference between wildtype and del34 heterozygous mice. Currently 
there is no other literature on the DNA methylation landscape of PKD1.  
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Cystogenesis is often likened to aspects of tumour formation174.  Woo et al. identified that 
91% of methylation changes found in ADPKD kidneys were hypermethylation (with 61% in 
genic regions and only 1% in promoters). In contrast, cancer studies have reported a global 
decrease in methylation175, resulting in the activation of repetitive elements, retrotransposons 
and oncogenes, with small areas of hypermethylation in tumour-supressing gene 
promotors120,175. 
It is possible that any difference in DNA methylation may only be found in the cyst lining 
tissue and since the del34 mouse model has few cysts and the DNA was extracted from whole 
kidney, any cyst specific methylation differences may have been diluted by the non-cyst cells 
and missed in the analysis as background noise. Histology of mouse del34 heterozygous 
tissue samples identified one confirmed cyst in a single heterozygous kidney, although only 
one section was examined from each kidney due to time constraints. It is likely that more 
cysts exist in the heterozygous tissues. The relative lack of cystic tissue, and known 
differences between mouse and human pathogenesis of the disease, may contribute to the lack 
of differences we see in methylation between the heterozygous and wildtype mouse tissues. 
In order to identify if DNA methylation differences are occurring in a heterozygous mouse 
model of cystic disease, the cells lining the cyst could be isolated and analysed. 
Microdissection of cyst lining epithelial cells has been performed before in our lab and DNA 
methylation analysis of this tissue in comparison to surrounding tissue and wildtype samples 
may reveal methylation differences that are lost in the ‘noise’ of whole tissue analysis, and 
that are associated with cystogenesis and perhaps the second hit mechanism. The 
microdissection technique does not produce sufficient DNA yield for our current methods of 
examining sample methylation. A modified reduced representation bisulfite sequencing 
(RRBS) method is currently being developed by members of our lab group that may be able 
to utilise very small quantities of DNA and could suit this purpose in future studies. 
66 
Potentially, and especially as the mouse gene body region analysed was not strictly a CpG 
island, DNA methylation differences may be located elsewhere in the mouse Pkd1 gene. To 
examine this, the entire gene could be examined using genome-wide bisulfite sequencing. 
The mouse Pkd1 contains 78% sequence homology113,172 with the human PKD1 and contains 
only five small CpG islands compared the six larger islands found in the human gene (see 
figure 3.11) according to NCBIs Strict algorithm158. Overall, Antequera and Bird (1993)176 
reported that the mouse genome contains approximately 37,000 CpG islands compared to 
45,000 in the human genome. Whether this difference has a functionally significant 
difference is unknown in current literature, although human research suggest that even non-
methylated CpG islands throughout the genome may be involved in mechanisms not directly 
related to gene expression, such as the maintenance of chromatin structure177. 
The mouse Pkd1 promotor was hypomethylated and the gene body hypermethylated in both 
wildtype and heterozygous samples and therefore the Pkd1 was likely to be transcriptionally 
active. To confirm this, we performed qPCR expression experiments targeting Pkd1. We 
found that Pkd1 is expressed in adult mouse kidneys and that surprisingly, expression levels 
were higher in del34 heterozygous mice when compared to wildtype.  Low expression of 
Pkd1 has been previously shown in some hypomorphic mouse models of ADPKD57,178 and 
this observation is supported by the formation of cysts after the expression levels of Pkd151 
are decreased, although induction of disease by overexpression54 and increased expression of 
PKD1 or polycystin-1 in human ADPKD tissues has been reported53,179,180. This suggests that 
PKD1 gene expression is very carefully regulated in the kidney and any significant changes 
to PKD1 expression in either direction is capable of initiating the disease. The del34 mouse 
model produces a truncated Pkd1 mRNA43 and the Zhou lab group that developed the del34 
mouse model published a paper in 2001178, which identified that the del34 homozygous and 
heterozygous mutants produced both wildtype and ~14 kb and ~11 kb mutant transcripts of 
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Pkd1. It would be interesting to identify which transcripts are showing the increased 
expression in our samples, and this could be done using a second set of primers downstream 
of the del34 disruption that would amplify only the wildtype allele. The proportion between 
the two expression datasets may indicate which allele is being predominantly expressed in 
heterozygous mice. Our expression data revealed that the embryonic del34 homozygote 
showed the highest expression of all samples analysed, which indicates that the mutant allele 
may be overexpressed, although only one sample was used in the analysis. Additional 
analysis on the expression of the PKD1 protein and miRNAs within the PKD1 gene would 
further clarify additional gene regulatory effects of the del34 mutant. 
Analysis of the products of human PKD1 in ADPKD shows a large variety of truncation and 
non-truncating mutant transcripts11. As we see a difference in Pkd1 expression in the del34 
heterozygous samples when compared to wildtype, but no difference in methylation in the 
two regions examined, potentially methylation may not be involved in the second hit in the 
del34 mouse model, or the DNA methylation changes may occur elsewhere in the gene. 
As no DNA methylation differences and a lack of cysts were identified in the del34 mouse 
model, and in addition to the unusual finding of 91% hypermethylation changes in human 
ADPKD by Woo et al., (2014)104, we decided to expand the limited human DNA methylation 
data by using reduced representation bisulfite sequencing (RRBS). This technique generates a 




Chapter 5: Human DNA methylation analysis of PKD1 
5.1 Summary of RRBS data analysis 
To add to the limited published data available on DNA methylation of the human PKD1 gene 
in cystic samples, we have compared the methylation landscape of human PKD1 and 
ADPKD related genes in wildtype and ADPKD kidney tissues. Five human kidney samples 
were analysed using reduced representation bisulfite sequencing (RRBS), two from ADPKD 
cystic kidneys with the remaining three from wildtype age-matched kidneys. This technique 
gives, representative methylation data from ~85% of CpG islands across the genome. Prior to 
sequencing, multiple steps required sample quality and quantity checks before proceeding 
with the protocol. 
The wildtype human kidney tissues were obtained from the Christchurch Tissue Bank162 after 
being removed from patients undergoing surgical procedures to remove renal tumours. The 
samples were taken from healthy cortical tissue as far from the renal tumour as possible. The 
two human ADPKD tissue samples were used from donated tissue. All samples were stored 
and used under the approval by the Otago Human Ethics Committee H15/110.  
 
5.1.1 First size selection 
To gain a representative look at CpG islands across the human genome, MspI digested and 
adapter ligated human library preparations of two ADPKD and three wildtype kidney DNA 
samples (section 2.8.2 and 2.8.3) were run on a NuSieve gel and the DNA sliced from the gel 
between the 150 and 325 bp bands (adjusted to include the adapter size, these bands were 
chosen to select for a representative sample of ~85% of all CpG islands in the genome) of the 
25 bp DNA ladder. The DNA samples were not exposed to UV light due to the risk of 
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degradation and therefore the DNA ladder was cut from the gel and imaged under UV light 
separately. The 150 and 325 bp bands were then marked and the distances measured on the 
gel. A small section of each lane containing DNA was then removed from between those two 
measurements for continuing library preparation. The remaining gel pieces were then placed 









Figure 5.1: First size selection gel extraction accuracy check. Reduced representation bisulfite sequencing 
(RRBS) requires only MspI digested fragments between 150 and 325 bp. The DNA samples cannot be exposed 
to UV so the ladder was removed and imaged separately (A). The distance to the 150 bp and 325 bp bands were 
then measured using a ruler under UV light and the remaining gel sliced using the measure lengths at the 







25 bp ladder   Sample 3    Sample 4       Sample 5
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5.1.2 Semi-quantitative PCR of library DNA 
 
Large-scale amplification of DNA samples requires a number of PCR cycles that will yield 
sufficient quality, while avoiding the potential errors that can arise from excessive 
amplification. Every sample was subjected to two semi-quantitative PCR reactions at 15 and 
20 cycles. The PCR products were then ran on NuSieve gels to determine the suitable number 
of amplification cycles (Figure 5.2). The electrophoresed gels were visualised under UV and 
the intensity of the 15 and 20 cycle PCR lanes for each sample was compared with the 
predetermined number of amplification cycles decided by Drs. Rodger and Chatterjee who 
developed the protocol. The NuSieve gel for samples 1 and 2 showed little intensity (figure 
5.2 A) between the size selected 150 and 325 bp regions and comparison between the 15 and 
20 PCR lane intensity was difficult. The NuSieve gel is electrophoresed for a long time (~90 
minutes), risking the possibility for complete consumption of ethidium bromide in the 
solution. The failed gel had not been run using fresh running buffer and that was believed to 
be the cause for the lack of fluorescence. Rather than performing another semi-quantitative 
PCR, both samples 1 (ADPKD08) and 2 (ADPKD07) were estimated to require 20 cycles for 
large-scale, to conserve the limited quanitity of library DNA. Samples 3,4 and 5 (Wildtypes 
H3, E1 and G2 respectively – figure 5.2 B) suggested cycles of 15, 18 and 20 respectively. 
The gel images in figure 5.2 also indicated the accuracy of the first round of size selection, as 
a perfectly size selected library would show the most fluorescence between the 150 and 325 
bp regions. Samples 3, 4 and 5 showed fluorescence consistant with accurate size selection. 
Due to the failed gel for samples 1 and 2, the accuracy of the first size selection was not able 

















Figure 5.2: Semi-quanititative PCR of RRBS libraries. Intensity of the size selected RRBS libraries was used to 
determine the most appropriate number of amplififcation cycles for large-scale PCR. A failed gel did not 
produce sufficient fluorescence in either lane for both samples (A), and this was believed to be caused by 
reusing gel running buffer for a second time or consuming all of the ethidium bromide. B – A successful gel 
with strong fluorescence between the 150 and 325 bp bands indicated the first size selection was successful. 
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5.1.3 Final size selection 
 
Before final purification of the libraries, the samples were size selected again to remove any 
fragments outside of the desired 150 – 325 bp range. 
 
 
Figure 5.3: Second size selection gel extraction accuracy check. The RRBS libraries were size selected for a 
second time before purification. Gels fragments were cut at the estimated 150 and 325 bp bands (represented by 
the bracket) using the method described in Section 2.8.4. Examination of the gel under UV light following 
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5.1.4 Sequencing quality 
 
The DNA libraries were sequenced by New Zealand Genomics Limited (methods section 
2.8.7 and 2.8.8) and were received with quality control reports generated by the program 
FastQC164 (V 0.11.3). All samples were of high quality with zero sequences tagged as ‘poor 
quality’. The sequence quality per base (Figure 5.4) showed high Phred quality (>30) scores 
of 34-36 (~1 in 5000 probability of incorrect base call) with typical gradual decline towards 
the end of the read. 
DNA base content at each position of the sequenced reads of one of the samples is shown in 
Figure 5.5, where the characteristic first three bases of CGG (methylated cytosine) or TGG 
(not methylated) indicate successful MspI digestion. Low cytosine scores across the reads 
also indicate successful bisulfite conversion with the gradual increase at the end of the read 
attributable to the multiplex adapters which contain methylated cytosines. Additional 
alignment reports generated by Bismark167 confirmed that bisulfite conversion was successful 











Figure 5.4: The base quality control data of a sequenced RRBS library (Sample 5). Base quality scores across 
each position of the total reads. The X axis depicts the base position along the reads (maximum read length of 
100 bp). Y axis is Phred quality score, with a score of 35 corresponding to a 1 in 5000 probability of wrong base 
calling. The blue line shows the mean quality score at each position, with the black error bars representing the 
lower (10%) and upper (90%) percentile range (several go beyond the top of the graph). The gradual decline of 















Figure 5.5: The sequence quality control data of a sequenced RRBS library (Sample 5). The percentage of each 
base of all reads for one sample (100 bp max read length) is shown. The X-axis shows positions along the read, 
with the Y-axis representing the percentage value for proportion of the bases at each position. The first three 
bases are consistently CGG and TGG which confirms the MspI digestion was successful. The considerably 
lower proportion of cytosines across the read (excluding the adapter readings towards the 100 bp end) confirms 








5.1.5 Integrated Genome Viewer of PKD1 
 
The DNA sequenced reads were aligned using Bismark aligning tools as discussed in section 
2.8.9. Integrated Genome Viewer (IGV) was used to visualise the aligned libraries. The 
HG19 human genome (supplied in the software) was used as a reference to align each library. 




Figure 5.6: The methylation landscape of the human PKD1 gene. ADPKD07 (1), ADPKD08 (2), WILDTYPE 
E1 (3), WILDTYPE G2 (4) and WILDTYPE H3 (5) RRBS data was aligned and visualised against the human 
reference HG19 PKD1 track. Red indicates a methylated CpG, blue unmethylated. Orange boxes indicate areas 
of the PKD1 gene that were hypermethylated in ADPKD samples compared to the wildtype samples. Green 
boxes indicate areas where the PKD1 was gene hypomethylated in ADPKD samples compared to the wildtype. 









The aligned RRBS sequence data reveals some areas of methylation difference between 
ADPKD and wildtype samples (Figure 5.6). The PKD1 gene body region where read 
coverage was available appeared to be hypermethylated in all samples. Several regions 
including the promotor and exon 4 were hypomethylated in all samples. Two intronic areas 
between exons 1 and 2 appeared to be hypomethylated in the ADPKD samples compared to 
the wildtypes tissues, whereas an intronic region between exons 33 and 34 was 
hypermethylated in the ADPKD samples. Exon 42 also showed hypermethylation in the 
ADPKD samples, which is close to the region reported by Woo et al., (2014)104 to be 
hypermethylated in ADPKD tissue. They identified an increase in DNA methylation in PKD1 
exon 43, although unfortunately no reads were obtained for exon 43 using the RRBS method 
in this study. Images of these specific regions with accurate genomic coordinates can be 
found in Appendix 6. 
The paper by Woo et al., (2014)104 listed several other genes that were found to be 
hypermethylated in their ADPKD samples, when compared to wildtype kidney samples. 
These genes were examined in our data and the results summarized in the table below. 
“ADPKD samples” indicates the comparison between the ADPKD and wildtype samples and 
any differences noted between the two datasets were listed by their location in the gene. 
Additional genes (BCAR1, COL1A1, PAX2 and STAT5) that were detected during the IGV 
and ANOVA analyses were also included in table 5.1. These results indicate gene specific 





Table 5.1: IGV analysis on genes reported as hypermethylated in ADPKD samples by Woo 
et al., (2014). 
Gene Function ADPKD samples 
ZFAT Ion transport No difference 
OSTA/SLC51A Ion transport No difference 
P2RX4 Ion transport No difference 
ATP4B Ion transport No difference 
TRPV1 Ion transport No difference 
SLC22A18 Ion transport Hypermethylated and hypomethylated in several 
intronic regions 
LCK Calcium signalling Hypomethylated in promotor 
CHRNA10 Calcium signalling No difference 
CLDN9 Calcium signalling No difference 
CACNA1H Calcium signalling Hypermethylated and hypomethylated in several 
intronic regions 
SYMPK Cell adhesion Hypermethylation in exon 20, hypomethylation 
across exons 26 and 27 
SPG7 Cell adhesion No difference 
SEMA4D Cell adhesion Hypermethylation in exon 17 
LGALS4 Cell adhesion No difference 
DSG4 Cell adhesion No difference 
MUC5B Cell adhesion No difference 
BCL2 Cell morphogenesis No difference 
LIG1 Cell morphogenesis Hypomethylation in intronic region between 23 and 
24 
SALL1 Cell morphogenesis No difference 
SOX10 Cell morphogenesis No difference 
FOXI1 Cell morphogenesis No difference 
TMEM176B Cell morphogenesis No difference 
DTX1 Development No difference 
CCDC88C Development Hypomethylation in one intronic region fragment 
between 3 and 4 
CSNK1G2 Development No difference 
NOTCH1 Development Hypermethylation in exon 5 
NOTCH2 Development No difference 
WNT4 Development No difference 
WNT7A Development No difference 
WNT9B Development No difference 
WNT11 Development No difference 
HDAC1 Chromatin remodelling No difference 
DOT1L Chromatin remodelling Hypomethylation in exons 12 and 24 
JMJD3/KDM6B Chromatin remodelling No difference 
EHMT1 Chromatin remodelling Hypermethylation in intronic region between 8 and 9 
EHMT2 Chromatin remodelling No difference 
PKD1L1 Ion transport No difference 
   
BCAR1 Cell adhesion migration, invasion, 
apoptosis and hypoxia* 
Hypermethylation in exons 5 and 7 
COL1A1 Component of collagen* Hypomethylation in exons 5 and 48 
PAX2 Transcription regulation* Hypomethylated across 3’ end of gene including 
exons 10 and 11 and the UTR region. 
STAT5 Component of JAK/STAT 
pathway* 
Hypomethylation in exons 2 and 3 
* Gene functions taken from NCBI database158 
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Functions listed for genes that do not contain an asterix in table 5.1 are provided by Woo et 
al., 2014104. Gene functions that are asterixed are taken from the gene summary displayed in 
the NCBI database158. 
Of the 37 genes reported as showing hypermethylation in ADPKD tissues compared to 
wildtype tissues in the Woo et al., (2014)104 paper, we identified six genes that showed 
regions of hypermethylation (when compared to wildtype samples), with three of these also 
showing regions of hypomethylation in the same gene. In total, seven genes show at least one 
region of hypomethylation, with 27 showing no difference at all. Of the four other genes 
investigated; BCAR1 displayed hypermethylation in two exons; with the remaining three 
(COL1A1, PAX2, STAT5), showing hypomethylation in at least two exons. 
 
5.1.6 ANOVA statistical identification of differentially methylated regions 
  
An analysis of variance (ANOVA) statistical test was performed on all RRBS fragments to 
identify fragments throughout the genome that have the largest proportional difference in 
methylation between the ADPKD and wildtype sample reads. Table 5.2 lists RRBS fragments 
with the chromosome and genomic location (Chr#, start, end), the length of the fragment, as 
determined by the overlap of sequence reads and varies either side of the average read length 
of 100 bp and the amount of CpGs that fragment contains. The “MethDiff” indicates the 
proportion of methylation differences between the ADPKD and wildtype samples for that 
fragment. The data was sorted to show the most hypermethylated ADPKD fragments (>0 




Table 5.2: Top differentially methylated RRBS fragments in the human genome.  
 
 
The ANOVA test (Table 5.2) when sorted for the top ten most hypermethylated fragments 
revealed several genes that are involved in pathways that are related to ADPKD such as: 
PKD1; TOB2 (cell cycle progression); GPR56 (cell adhesion); ZNF750 (associated with mis-
differentiation) and WNT9B (associated with renal tubule development and renal 
cystogenesis). 
The ten most hypomethylated regions in the ADPKD tissue compared to the wildtype 
samples also revealed genes involved in similar pathways including: PAX2 (associated with 
kidney development, cancer and ADPKD, the 3’ end of this gene was also identified to be 
Hypermethylated ADPKD fragments      
Chr# Start End Length CpGs P-value F-value MethDiff Gene 
7 592961 593019 59 4 0.00670305 45.27 0.6551 PRKAR1B 
16 2147611 2147671 61 3 0.00317369 76.06 0.6413 PKD1 
22 41846168 41846260 93 5 0.00582055 49.97 0.6344 TOB2 
3 111431353 111431517 165 4 0.0104055 33.16 0.6221 ZBED2 
4 53714737 53714836 100 3 0.0212211 19.73 0.6182 RASL11B 
16 57657149 57657213 65 3 0.00514093 54.49 0.6169 GPR56 
17 80818649 80818771 123 7 0.0564382 9.16 0.6101 ZNF750 
12 132865276 132865388 113 9 1.48E-06 13046.79 0.6041 GALNT9 
17 44942189 44942283 95 2 0.00621706 47.72 0.6025 WNT9B 
22 50250431 50250474 44 4 0.0295304 15.36 0.5999 ZBED4 
         
Hypomethylated ADPKD fragments      
Chr# Start End Length CpGs P-value F-value MethDiff Gene 
4 83230518 83230585 68 3 0.00115085 151.88 -0.8759 ENOPH1 
10 102588174 102588314 141 7 0.00205013 102.59 -0.6637 PAX2 
17 73839504 73839629 126 3 0.00933566 35.83 -0.645 UNC13D 
18 77266975 77267020 46 2 0.0118251 30.26 -0.6317 NFATC1 
10 102589102 102589150 49 4 0.0173507 22.9 -0.6303 PAX2 
19 933115 933292 178 8 0.0057767 171.61 -0.6235 C19orf22 
17 78866065 78866211 147 6 0.00092236 176.41 -0.6186 RPTOR 
1 163076804 163076885 82 3 0.0786753 11.23 -0.6166 NUF2 
1 146704307 146704365 59 3 0.00166631 118.15 -0.6153 FMO5 
6 30653437 30653520 84 3 0.00276706 83.57 -0.6115 PPP1R18 
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hypomethylated in the IGV analysis) and RPTOR (regulates mTORC1, which is associated 
with ADPKD, cell growth and survival). Most fragments have a raw P-value below 0.05 and 
therefore the difference in methylation between the ADPKD and wildtype samples at that 
fragment may indicate a significance difference. The F-values are all >1.0 and further 
indicate that the variation of the group mean is greater than expected by chance alone (An F-
value close to one suggests the mean variation between the two fragments is likely to be due 
to chance). The ZNH750 and NUF2 genes appeared not significant with raw p-values of 















Chapter 6: Discussion for human methylation analysis 
of PKD1 
 
6.1 Human PKD1 methylation 
 
To determine and compare the methylation landscape of the human PKD1 gene and 
associated cystogenesis-related genes against the limited published literature, we used the 
RRBS technique to reveal a representative dataset of methylation differences between 
ADPKD and wildtype kidney samples across the genome. 
Woo et al., (2014)104, which performed genome-wide bisulfite analysis on human ADPKD 
samples reported hypermethylation of the PKD1 gene, and specifically published an increase 
in exon 43 gene body methylation in patients with ADPKD. They correlated this with a 
decrease in expression of PKD1. To investigate the methylation landscape of PKD1 in our 
samples, we performed reduced representation bisulfite sequencing (RRBS) on two kidney 
samples for ADPKD patients, and three wildtype kidney samples. The methylation status of 
the PKD1 and other interacting genes were examined with the Integrative Genomics Viewer 
(IGV). The RRBS technique was chosen because it is considerably cheaper than whole 
genome bisulfite sequencing123 and produces a representative dataset of ~85% of the CpG 
islands within the genome124. Because of this, the information available for each gene varied 
depending on the genomic location of the fragments. By comparing the methylation status of 
the RRBS fragments in both the ADPKD and wildtype samples using IGV, regions in 
ADPKD related genes that appeared to be differentially methylated were also identified. 
PKD1 appeared to be hypomethylated in the promotor region and hypermethylated in the 
gene body region across all samples, as was also seen in our mouse Pkd1 methylation 
analysis. This is what is expected for an active gene88 and suggests that PKD1 is expressed in 
ADPKD samples. Four regions in PKD1 were found to be differentially methylated in 
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ADPKD samples compared to wildtype samples, two hypomethylated fragments towards the 
intronic promotor region, one hypermethylated region in the intronic gene body and one 
hypermethylated region in exon 42. Woo et al. reported an increase in methylation of exon 43 
in ADPKD tissues compared to wildtype tissues, which may be supported by the increase that 
we identified in exon 42, although no data on exon 43 was obtained in our dataset. Several 
other genes were reported as showing overall hypermethylation by Woo et al (Table 5.1). 
Whole gene methylation comparisons may miss important regions of differential methylation, 
as a gene that shows overall hypermethylation may contain discrete regions of 
hypomethylation and hypermethylation. To determine if the differentially methylated regions 
in our study could influence expression and splicing, transcriptome and RT-qPCR 
experiments would have to be performed. Due to time constraints, this was not able to be 
examined during the course of this research. Potentially if these DNA methylation differences 
are able to influence alternative splicing patterns, then there is potential for PKD1 DNA 
methylation to play a role in ADPKD pathogenesis.    
Genes that were identified as being hypermethylated in ADPKD samples in the Woo paper 
were also investigated in our dataset using IGV (Table 5.1). Many of these genes were 
associated with key characteristics of ADPKD such as cell adhesion, cell regulation and 
differentiation and renal development. Genes such as SLC22A18, LCK, CACNA1H, SYMPK, 
SEMA4D, LIG1, CCDC88C, NOTCH1, DOT1L and EHMT1 all showed at least one 
differentially methylated fragment whereas all the remaining genes (found in Table 5.1) 
appeared to have no methylation differences in the CpG island enriched dataset that was 
obtained via the RRBS method. The addition of more ADPKD and wildtype samples for 
analysis and more read coverage using techniques such as genome-wide bisulfite sequencing 
would provide more support to these conclusions.  
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Analysis of variance (ANOVA) statistical testing was also performed on all the RRBS 
fragments to find regions that were the most hypermethylated and hypomethylated in the 
ADPKD samples compared to the wildtypes. PAX2 was identified in the ANOVA test as 
having several fragments that were suggested to be significantly (<0.05) hypomethylated in 
the ADPKD samples and this was confirmed by investigating the gene in IGV. PAX2 gene 
dosage influences cyst formation in the del34 ADPKD mouse model181 and reducing PAX2 
expression has been shown to increase apoptosis and reduce renal cyst progression182. The 
IGV data revealed that the hypomethylated region in the PAX2 gene is found in the 3’ end of 
the gene covering exons 10 and 11 and the untranslated region, which may be involved in 
DNA organisational regulatory mechanisms such as enhancer and silencer regulation and no 
literature has currently examined this part of the gene for regulatory elements. This could be 
investigated further using the chromosome conformation capture technique, which uses 
formaldehyde to preserve DNA-DNA interactions. This has been performed on a large 
number of genes and model organism, including interactions between the developmental 
polycomb repressive complexes 1 and 2 (PRC1 and 2) and PAX2183. Any correlation between 
the hypomethylated region and PAX2 expression levels may be determined by gene 
expression analysis such as qPCR. Because the differentially methylated RRBS fragments 
only provide data on CpG rich regions, the methylation differences identified by IGV and the 
ANOVA test (Figure 5.6 and Table 5.2), may not reflect the methylation landscape of the 
entire gene, although the regions identified may influence alternative splicing and 
transcription stability. The identified regions in these genes provide a good base for further 
investigation. 
There is very little research on the methylation landscape of the human PKD1 or mouse Pkd1 
genes and other similar genes involved in polycystic kidney diseases. This study focused on 
PKD1 and other cystogenesis specific genes. Further methylation analysis of the CpG island 
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enriched genome will be possible by analysing the complete RRBS data for the five human 
tissues investigated in this study, to examine global trends and differentially methylated 
regions. A variety of tools exist to further analyse this data such as differential methylation 
analysis package (DMAP)184. 
Genome-wide bisulfite sequencing could be used to investigate the genome-wide methylation 
landscape with more coverage than the RRBS method used in this study. In addition, targeted 
bisulfite sequencing could be performed on selected genes to identify methylation differences 
with more coverage and greater depth than a genome-wide approach.  
As well as global changes in DNA methylation that are associated with cystogenesis, the 
possibility still exists that DNA methylation changes in the remaining unmutated allele of the 
PKD1 gene could, in some cysts, be a second hit. RRBS requires a considerable quantity of 
starting DNA to ensure good quality libraries for sequencing. Enhanced methodology is 
being developed in this laboratory to greatly reduce the quantity required for this process, and 
to potentially allow RRBS analysis at a single cell level in both human and mouse samples. If 
the RRBS process is able to be performed on isolated cyst epithelial cells from either mouse 
or human cysts, then the methylation landscapes would be able to be compared directly on a 
cell to cell level which may give more data in regards to the two hit hypothesis. As an 
extension of this area of research, an investigation of the DNA methylation landscape of 
multiple cell lines derived from individual cysts from the same patients is currently being 
undertaken in this laboratory. All cell lines contain the same germ-line mutation but may 




Our results in this study indicate that PKD1 has a hypomethylated promotor but areas of both 
hypomethylation and hypermethylation in the gene body in ADPKD samples. Further data in 
the form of more gene coverage and more samples may further support this conclusion. This 
research contributes to the existing understanding of the role methylation plays in 

















Chapter 7: Bio-distribution of C3-G12 in mice 
 
Targeted delivery molecules have been developed for a wide range of diseases and organs to 
effectively delivery a therapeutic agent to the correct tissue with higher concentration and 
less off-target side-effects than treatment with the drug alone. 
To identify the bio-distribution and kidney specific targeting ability of the C3-G12 peptide in 
a mice kidney, liver, lungs, heart and spleen, the fluorescent marker Cy3.5 was conjugated to 
the peptide by our collaborators (see methods section 2.9) and injected into mice by tail-vein 
injection. Current literature suggested that the C3-G12 peptide locates and is accumulated in 
the kidneys of mice and this research was performed to confirm this and show that the 
delivery of the peptide is possible in our hands before future projects involving the injection 
of peptide-drug conjugates. 
 
7.1 Comparative fluorescence standard curve 
Pilot experiments suggested that the Cy3.5 free dye and the C3-G12-Cy3.5 peptide conjugate 
had different fluorescence levels at the same concentration. To examine this and normalise 
the fluorescence between both solutions, a standard curve was created for the free dye. 
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Figure 7.1: Cy3.5 free dye quantity versus fluorescence standard curve. Each dot represents averaged 
fluorescence readings over two to six replicates. (Cy3.5 - 590 nm excitation/ 620 nm emission) 
 
The fluorescence was measured for seven dilutions of the free dye (1000 – 100 pmol) and 
was compared to the averaged fluorescence data to two dilutions of C3-G12-Cy3.5. 
The average fluorescence of the peptide-dye at 1000 pmol (202.5) matched the average 
fluorescence of the free dye at 100 pmol (206) , therefore 1/10 of the concentration of the 
peptide was used for free dye injections into mice. 
 
7.2 Free dye vs Peptide-Dye conjugate IV administration into mice 
 
Mice were injected with 1 pmol of free dye or 10 pmol of C3-G12-Cy3.5 pmol conjugate, 
administered by tail-vein injection and were culled at 3, 15 or 30 minutes post injection. 
Kidneys, heart, liver, spleen and lungs were removed and imaged. The levels of fluorescence 
are summarised in Table 7.1 based on the measured fluorescence intensity of each organ 
(Mean Gray Value as determine by ImageJ, section 2.12), with kidney images shown in 
Figure 7.2 and the remaining images in Appendix 7. 
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Figure 7.2: Fluorescent images of representative mouse kidneys after tail-vein injection with Cy3.5 (1 nmol) or 
C3-G12-Cy3.5 (10 nmol). Mice (~ 11 months) were culled at 3 minutes (three mice for each solution, n=3), 15 
minutes (n=2) and 30 minute (n=2) time points. Image exposure settings are tabled in Section 2.12. 
 
Vehicle control animals injected with DMSO and normal saline (NS) showed no fluorescence 
and background fluorescence was not visible under any length of exposure. Cy3.5 free dye 
showed slight fluorescence at the 3 minute time point in the kidney (Figure 7.2) but this was 
undetectable at the 15 time point, although very slight fluorescence was seen in one mouse 
liver and lungs at the 30 minute time point. Overall, this suggests that the free dye may be 
mostly cleared from the mouse system between 3 and 15 minutes and is not retained in 
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kidneys. The C3-G12-Cy3.5 peptide conjugate showed intense fluorescence at all time points 
in the kidney, with slight fluorescence identified in the liver and lungs at the 3 minute time 
point, eventually becoming barely detectable at 30 minutes. This suggest that the C3-G12-
Cy3.5 conjugate localises mainly to the kidneys and is retained there for at least 30 mins, 
with potentially a small amount retained in the liver and lungs, although this may be cleared 
from the system after 30 mins. No fluorescence was detected in the heart and spleen after any 











Chapter 8: Discussion for Bio-distribution of C3-G12 in 
mice 
8.1 C3-G12 peptide bio-distribution 
 
To investigate the possibility for kidney targeted therapies to treat ADPKD, the kidney 
specific properties of the C3-G12 peptide was examined in mice. We found that the C3-G12 
peptide conjugated to the fluorescent marker Cy3.5 accumulated in the mouse kidney and 
was maintained there for at least 30 minutes after IV injection. 
The original intention of this research was to use the FX-Pro in vivo small animal imager to 
examine the quantity and localisation of the C3-G12-Cy3.5 peptide conjugate inside live 
mice throughout multiple time points. All organs would then be able to be viewed 
simultaneously, and fluorescence levels quantified. Unfortunately the FX-Pro was in need of 
repair and after considerable effort on my behalf and that of department staff with the 
company involved, the FX-Pro was unable to be fixed. Instead, the accumulation and 
specificity of the C3-G12-Cy3.5 peptide conjugate in the mouse kidney, liver, lungs, heart 
and spleen was examined semi-quantitatively using an epi-fluorescence microscopy. We 
concluded that the peptide conjugate appeared to be retained in the kidney and accumulated 
there for at least 30 minutes, as evidenced by the fluorescent intensity of the peptide 
conjugate when compared with the free dye injections. The liver, lung, spleen and heart were 
also dissected and imaged at each time point. The liver showed slight fluorescence following 
Cy3.5 and C3-G12-Cy3.5 injections at three minutes, with fluorescence not detected at 15 
minutes. However there was a small amount of fluorescence detected following the Cy3.5 
injection in the 30 minute time point for the liver and lungs. This is unlikely to be technical 
inconsistency as all mice for the 15 and 30 minute time points were injected, culled, dissected 
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and the organs imaged within 30 minutes of each other. Potentially the mice at the 30 minute 
time point metabolised the Cy3.5 dye or C3-G12-Cy3.5 peptide conjugate slower or the 
fluorescence in these organs was minimal and towards the lower threshold for detection and 
simply wasn’t detected at the 15 minute time point.  
The retainment of the C3-G12 peptide in the kidney reconfirms what was previously 
published by Geng et al., (2012)154, where they identified the C3-C12 peptide conjugated to 
the green fluorescent marker FITC was retained in mouse kidneys for up to an hour after IV 
injection. They detected FITC fluorescence after IV injection of their peptide conjugate in 
five organs (kidney, liver, lung, spleen, heart) after 3 minutes post IV injection. In our study, 
after injection with free Cy3.5 by IV injection, a small amount of fluorescence was detected 
in the liver and lungs after the 3 minute time point but not in the heart and spleen. This may 
be due to differences in background fluorescence in the FITC and Cy3.5 molecules in mice. 
While our data suggests that the C3-G12 peptide is accumulated in the mouse kidneys, 
further analysis on the bio-localisation at the cellular level is required for confirmation. 
Kidneys that have been preserved from this study could be embedded and sectioned to 
identify specific tubule localisation under fluorescent microscopy. Due to the limited amount 
of peptide available, time points beyond 30 minutes were not examined. This could be 
performed in the future to determine the length of accumulation of the C3-G12 peptide in the 
kidney. 
A key issue with the whole body treatment of patients with renal disease therapies, is that the 
high concentrations are often required, and this may introduce considerable side effects128. 
The C3-G12 peptide could be conjugated to a methylation altering drug (or other treatment 
for ADPKD), allowing targeted delivery to the kidney. This would then be tested in suitable 
animal models to examine the effects of the drug on the cystic and healthy kidneys, and any 
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such side effects. Potentially the C3-G12 peptide could be conjugated to existing methylation 
altering drugs 5-Aza-2deoxycytidine and 5-Azacytidine or HDAC inhibitors that have been 
shown to reduce or slow cystogenesis and delivered into an existing conditional or inducible 
mouse model (section 1.6, table 1.1) that exhibits a disease phenotype similar to the human 
condition. 
Delivery molecules are currently being developed for use in a variety or organs and diseases 
including tumour-targeted cancer therapies129,130, blood-brain barrier crossing molecules185 
for use in diseases such as Alzheimer’s132, colon-targeted molecules for the likes of 
inflammatory bowel disease133, amongst many others. The most effective delivery molecule 
would be capable of efficient delivery of a wide range of conjugated drugs to the organ or 
disease of interest without accumulation elsewhere in the body and with a half-life that 
retains the molecule for the desired amount of time without any toxicity associated with the 
delivery molecule itself. Several different targeted delivery mechanisms have been developed 
specifically for kidney and renal diseases, including Pro-drugs, Nanoparticles, Lipososmes 
and Peptides, the latter which have the benefit of little to no toxicity in the body although 
enzymatic activity of the digestive system limits its use in oral delivery. 
This research has shown that in our hands the C3-G12 peptide does accumulate in the mouse 
kidney and is retained there for at least 30 minutes. This combined with the Geng et al., 
(2012)154 lab data suggests that the C3-G12 peptide may be suitable for the purpose of 
targeted delivery of conjugated therapies to the kidneys in mice, although further time points, 
whole body imaging of injected mice and other model species, investigation of the bio-
distribution of the peptide at the cellular level would be required to further characterise the 
effectiveness of the C3-G12 peptide as a targeted delivery mechanism for polycystic kidney 
disease.  
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Chapter 9: Final Discussion 
9.1 Final Summary Discussion 
Data on the methylation landscapes of the mouse Pkd1 and human PKD1 genes is lacking in 
the current literature and evidence for methylation as a mechanism for the proposed “second 
hit” to the PKD1 gene during ADPKD pathogenesis has not previously been investigated. 
Epigenetic changes have the potential to be a mechanism for this second hit and published 
literature has already established links between histone regulation changes and ADPKD. 
However, little research exists on the impact of DNA methylation on the pathogenesis of 
ADPKD. If DNA methylation is in fact a key mechanism in the second hit, there is possibility 
for a targeted therapy acting on methylation to restore PKD1 function, and possibly slow 
cystogenesis.  
The long term goal of this research is to target epigenetic changes in the kidney to treat 
ADPKD. Epigenetic modifying drugs such as the histone deacetylase (HDAC) inhibitors 
valproic acid (VPA) and trichostatin A (TSA) which have both been used to effectively 
reduce cyst growth and renal function loss in mouse models12,85. Concerns over the potential 
side-effects of whole body treatment of epigenetic modifying drugs suggests that the use of a 
kidney-specific targeted delivery molecule would be beneficial in the treatment of ADPKD. 
This research aimed to investigate DNA methylation in the mouse Pkd1 gene body region in 
both Pkd1 del34 heterozygotes and wildtype mice. This was combined with previous data on 
a region in the Pkd1 promotor to determine if any methylation differences may contribute to 
the theorised epigenetic “second hit” in ADPKD pathogenesis. To compare the mouse Pkd1 
DNA methylation against the human PKD1 methylation landscape and extend the limited 
human data available would also provide support for the identification for any methylation-
related second hits. Finally, the future goal of this project would be to incorporate the DNA 
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methylation data with an epigenetic altering therapy specifically targeted to the kidney. To 
examine the kidney specificity of a proposed targeted delivery peptide, C3-G12, the peptide 
was conjugated to a fluorescent marker and was injected into mice. Mice were sacrificed at a 
series of time points and the fluorescence of specific organs were viewed by fluorescent 
microscopy.  
The first part of this project utilised bisulfite treatment and cloning techniques to isolate a 
selected gene body region of the mouse Pkd1 gene in both del34 heterozygotes and wildtype 
mice, to identify if there was any difference in the level of methylation that may contribute to 
cystogenesis, as any methylation difference identified could be targeted for use in epigenetic 
modifying therapies that would be developed using the mouse model. Combined with data on 
a region in the Pkd1 promotor, we found there was no difference between the level of 
methylation in either regions in wildtype and del34 heterozygous mice. This is different to 
what was identified in human samples by a paper by Woo et al., (2014)104 where they used 
pyrosequencing techniques to identify an increase in exon 43 methylation in tissue from 
ADPKD kidneys which correlated to a decrease in PKD1 expression. Expression analysis of 
our mouse samples revealed consistently low expression of Pkd1 in wildtype samples, and 
higher expression in heterozygous. If methylation in the mouse Pkd1 gene is altering the gene 
expression level, it may be located elsewhere in the gene. To further investigate this, 
differences may be more easily identified by examining individual cyst lining epithelial cells 
and the rest of the CpGs in the Pkd1 gene could be examined by whole-genome bisulfite 
sequencing. If methylation differences do exist between the del34 mouse model and the 
human disease, then future therapies developed using this mouse model and epigenetic 
modifying drugs may not interact with the human disease in a similar manner.  
The current published literature on the human PKD1 DNA methylation landscape is lacking, 
and comparisons between the DNA methylation of the human PKD1 and mouse Pkd1 genes 
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could indicate if DNA methylation is in fact a conserved mechanism for ADPKD 
pathogenesis. To examine the DNA methylation landscape of the human PKD1 gene for 
comparison to the only published data currently available, the reduced representation bisulfite 
sequencing (RRBS) technique was used to gain a representative sample of the CpG island 
regions in the human genome. Several methylation differences were identified in PKD1 in 
ADPKD tissue, including separate regions of hypomethylation and regions of 
hypermethylation. This is in contrast to the paper published by Woo et al., (2014)104, which 
reported increased gene body methylation genome-wide and in the PKD1 gene. Potentially 
regions of hypomethylation were missed by Woo et al. when simply analysing whole gene 
trends. These areas may have functional importance relating to gene expression, although this 
would have to be investigated by expression analysis. Differences shown between our data 
and that of Woo et al. may be due to differences in technique. To analyse the DNA 
methylation of the entire genome, Woo et al., used methylated-CpG island recovery assay 
(MIRA), which utilises the affinity of the MBD2/MBD3L1 complex to methylated cytosines 
combined with micro array to produce data on CpGs throughout the genome186. A global 
methylation increase was described in ADPKD samples and individual genes (section 5.1.5) 
were presented as whole methylation differences. In contrast, we used the RRBS technique 
that uses the MspI restriction enzyme which splits the DNA at CCGG motifs and when 
combined with size selection, produces a CpG island enriched subset of the whole genome 
data. While neither methods appear to produce any methylation bias, there is potential that 
differences seen in our data are due to methylation information that was absent in the others 
dataset. Our data also identified an increase in DNA methylation in exon 42 of PKD1 in the 
ADPKD samples compared to wildtypes. This may support the finding by Woo et al., where 
they identified an increase in DNA methylation in exon 43 using bisulfite pyrosequencing 
targeted at this region and a region in the promotor for which they found no difference. Gene 
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body DNA methylation has been shown to be important for stable gene expression by 
suppressing disrupters of transcription such as repetitive sequences and transposons, as well 
as regulating enhancer and silencer sequences88,94-96. If the regions of hypomethylation and 
hypermethylation in the PKD1 gene in ADPKD samples are in fact functional and involved 
in the suppression of transcription disrupters or enhancers and silencers, then potentially 
DNA methylation may impact on the pathogenesis of ADPKD and may contribute to the 
second hit, indicating that disease may not be influenced purely by overall hypo- and 
hypermethylation but a more specific mixture of both. Addition of more ADPKD samples 
and genome-wide bisulfite sequencing would be advantageous to further investigate this 
possibility. 
To determine the suitability for targeted drug delivery into a mouse model, the C3-G12 
peptide, was conjugated to the fluorescent probe Cy3.5 and was injected at multiple time 
points into Balb/c mice. By comparison to control injections containing only free dye, it 
appears the peptide-dye conjugate accumulates in the mouse kidney and is retained there for 
at least 30 minutes. It does not appear to accumulate in any large quantity in the other organs 
examined. This result confirms kidney-specificity in our hands and further supports the 
conclusions by existing literature, where the C3-G12 peptide may be suitable candidate for 
use as a targeting kidney therapy delivery system. Investigation into where the peptide is 
accumulated on a cellular level is important, as cystogenesis forms in lumen-lining epithelial 
cells predominantly in the distal tubule and collecting duct and these would need to be 
targeted in the therapy. Identification of where the C3-G12 peptide is being absorbed could 
be analysed by use of techniques such as multi-photon microscopy. 
Confirming the kidney specificity of the C3-G12 peptide reinforces its potential as a targeted 
delivery molecule that can be conjugated to a number of drugs for treatment of ADPKD 
including methylation modifiers 5-Aza-2deoxycytidine and 5-Azacytidine and drugs such as 
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Octreotide187 or Tolvaptan188 that are currently being validated for future clinical trials189. 
The use of a targeted delivery molecule allows a higher concentration to be administered 
directly to the diseased tissue and side-effects from whole body treatment can be avoided128. 
Multiple targeted delivery molecules are currently being researched (introduction section 
1.11), and while peptide based delivery systems offer some advantages, namely inherent non-
toxicity in the body and higher efficiency than other methods, they also have a relatively 
short half-life which can decrease the longevity of the treatment in the body and the 
enzymatic activity of the digestive system may disrupt the peptide, limiting its effectiveness 
by oral delivery152. 
This research project provides the base work for a future project that would incorporate the 
methylation information in ADPKD with the goal to conjugate an epigenetic-altering drug to 
the C3-G12 peptide and selectively deliver it to the kidneys of an ADPKD mouse model and 
look for epigenetic modifications that may be altered by the drug and if this has any effect on 
the disease phenotype, with the long-term goal of development of a human therapy. 
 
9.2 Limitations of this study 
 
There are several ways this study could have been improved. Firstly, issues with cloning 
efficiency and bacterial growth limited the quantity of Pkd1 gene body sequences obtained 
from the cloning work. Multiple improvements were made to the protocol to attempt to 
improve transformation efficiency of the DH5α bacteria and the quality of sequence data. A 
similar issue was also encountered while cloning the promotor region of the Pkd1 during my 
Post Graduate Diploma research although bacteria cloned with the gene body region appeared 
to grow better with more colonies than the promotor region fragments. This may be due to an 
inherent toxicity of the cloned Pkd1 promotor region, or the improved protocol did produce a 
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more efficient and effective cloning method for the gene body fragments. Increasing the 
number of quality sequences would allow a larger sample size for a more powerful statistical 
analysis. A more efficient and streamlined protocol would have allowed time for the 
examination of other CpG islands in the mouse Pkd1 gene. 
The del34 mouse model is one of many animal models of human ADPKD. Like all Pkd1 
knockout mouse models available, the del34 mouse is embryonically lethal when 
homozygous for the del34 disruption but the heterozygous mouse does not develop the same 
number of cysts or loss of renal function that the human disease exhibits156. Other mouse 
models exist that contain an inducible second hit to the wildtype Pkd1 allele to more rapidly 
and accurately represent the pathology of the human disease and are useful for the 
investigation of pathogenesis after a somatic second hit57. These mice would be useful for 
studying the effect of a tissue targeted methylation inhibitor in slowing cyst formation. 
However, they do not reflect the genetics behind the pathogenesis of human ADPKD and 
may not be informative on the epigenetic mechanisms that may facilitate a spontaneous 
second hit in somatic cells. Del34 mice are one of several Pkd1 heterozygous knockout 
models that all exhibit similar pathologies. Although they do not accurately reflect cyst 
formation in human ADPKD, better models of the human disease for the purpose of 
investigations into the development of somatic second hits do not currently exist. Despite its 
limitations, the del34 could be a suitable model for the purposes of this study if cyst-lining 
cells can be analysed and is still potentially informative for the investigation of the ADPKD 
second hit mechanism by comparison to the human disease. 
A paper by the Fuso et al., (2015)190  has identified methylation of non-CpG cytosines in 
some tissue types, resulting in a bias in methylated primer design, as most primer design 
software assume that non CpG cytosines are inherently not methylated. The primers used for 
this research were designed on that assumption that the non-CpG cytosines in the binding 
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region were not methylated. The level of methylated non-CpG cytosines is tissue-specific and 
has not been determined in kidney tissue, therefore it is possible that a bias was introduced as 
the primers may not have bound to template DNA strands with non-CpG cytosine 
methylation and therefore not amplified those strands. This may be worth investigating in 
future. 
The tissues used for the RRBS analysis were taken from whole kidney tissues from age 
matched patients. The two cystic samples were considerably cystic and fibrous with no ability 
to characterise what section of the kidney they originally came from. Additional ADPKD 
tissue samples are difficult to obtain as kidneys are not usually removed prior to renal 
transplantation and biopsies are not performed. Furthermore, due to its high expense, kidney 
samples are not usually genotyped for PKD1 or PKD2 mutations. The wildtype tissues were 
obtained from the cortical region of individuals undergoing renal cancer surgery and were 
removed from healthy tissue as far away from the tumour as possible. There is potential for 
methylation differences to exist between different cells within an organ, and differences seen 
between the samples may in fact reflect different regions of the kidney or different cell types 
rather than a difference in healthy and cystic tissue. Healthy tissue can be difficult to obtain 
as healthy kidneys are not usually operated on in a manner that would facilitate removal of 
tissue. Ideally more ADPKD and healthy tissues would be available for a wider study 
including larger genome analysis with more coverage of the genome. Cell lines created from 
single separate cysts from the same patient are able to be analysed to investigate the 
methylation differences between individual cysts. 
In summary, this research has contributed to the current understanding of the pathogenesis of 




The aims of this research were three-fold: to compare methylation in the Pkd1 gene in both 
Pkd1 heterozygotes and wildtypes to determine if any methylation differences between the 
two may support an epigenetic “second hit” in ADPKD pathogenesis; to extend the limited 
data available of the human PKD1 methylation landscape using RRBS and to compare the 
methylation between ADPKD and wildtype tissues; and to test the ability of the C3-G12 
peptide to localise to the kidney in mice using the Cy3.5 fluorescent probe. 
I have identified that a region in the promotor of the mouse Pkd1 is hypomethylated in both 
wildtype and Pkd1 heterozygous mice and that a region in the gene body is hypermethylated 
and shows no significant difference between wildtype and Pkd1 heterozygous mice, 
suggesting that if any methylation differences exist, they may be found elsewhere in the Pkd1 
gene. In both human ADPKD and wildtype tissue samples, I found that the PKD1 promotor 
is hypomethylated and the gene body is hypermethylated with an increase in methylation 
identified in exon 42 in ADPKD tissues. This supports a potential role for DNA methylation 
in ADPKD pathogenesis. 
I also observed the accumulation of the C3-G12 peptide in the mouse kidney with retainment 
of over 30 minutes and little to no fluorescence was observed in the heart, liver, lungs and 
spleen. This suggests that the peptide is able to specificity target the kidney and may be a 
suitable candidate for kidney-specific drug therapies. 
This research provides new data on the mouse and human methylation landscapes in ADPKD 
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Appendix 1 – Solutions 
Supplementary Table 1: Solutions used in this research 
LB + agar + ampicillin plates (LBAA) 
Bacta-Trypton 10g 
Yeast Extract  5g 
NaCl  10g 
Make up to 1 litre, pH to 7. 
Agar  15g (for 1.5% plates) 
Autoclave solution 
Ampicillin  1 μl per ml (100 mg/ml) 
 
SOC media 
KCl  0.019g 
MgCl2 0.20g 
MgSO4 0.25g 
Yeast Extract 0.5g 
NaCl  0.6g 
Tryptone 2.0g 
Make up to 100 ml, autoclave.  
 
10x TAE 
TRIS  48.4g 
Glacial acetic acid 11.4 ml 
EDTA  3.7g 
pH to 8, make up to 1 litre. 
 
Normal Saline (9%) 
Sodium Chloride 9 g 









Supplementary Figure 1 - TOPO 4.0 vector by Invitrogen 
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Appendix 3 – Primers used throughout study 





muPKD1ex37F (qPCR) TTGGCAAAGGAGGAAGCTCG 
muPKD1ex38R (qPCR) TGGGGATGCTTCTTGCCATG 
MouseGAPDHF (qPCR) TGCACCACCAACTGCTTAGC  
MouseGAPDHR (qPCR) GGCATGGACTGTGGTCATGA  
MouseHPRTF (qPCR) GCTTTCCCTGGTTAAGCAGTACA  
MouseHPRTR (qPCR) GAGAGGTCCTTTTCACCAGCAA  
NeoFII (del34 genotyping) CAGCGCATCGCCTTCTATC 
MR50 (del34 genotyping) CTTTAATCCCTGCACTCAGGA 










Appendix 4 – Del34 mouse data 
 
Supplementary Table 3 – Pkd1 study mouse age and genotype. Sample 1314 that was re-
genotyped as a heterozygous is italicised.  
 
Sample Mouse Genotype Age (months) 
1289 Heterozygous 19 
1293 Wildtype 19 
1314 Heterozygous 18 
1319 Heterozygous 18 
1324 Wildtype 17 
1327 Wildtype 17 
1388 Heterozygous 13 


































Supplementary Figure 2 – Close up of IGV methylation differences in human PKD1. 
ADPKD07 (1), ADPKD08 (2), WILDTYPE E1 (3), WILDTYPE G2 (4) and WILDTYPE 
H3 (5) RRBS data was aligned and visualised against the human reference HG19 PKD1 
track. Red indicates a methylated CpG, blue unmethylated. A – ADPKD samples are more 
hypermethylated in PKD1 at exon 42 (genomic location of image ch16 2,141,238 to 
2,142,226). B - ADPKD samples are more hypermethylated in PKD1 between exons 33 and 
34 (ch16 2,146,209 to 2,148,064). C - ADPKD samples are more hypomethylated in PKD1 
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Appendix 7 – Fluorescence in mouse organs 
 
   
Supplementary Figure 3 – Mouse organs dissected from mice sacrificed at three minutes. A – 
Injected with Free Cy3.5 Liver, B - C3-G12-Cy3.5 Liver and Lungs (C). 
 
Supplementary Figure 4 – Mouse organs dissected from mice sacrificed at fifteen minutes. A 
– Injected with C3-G12-Cy3.5 Liver. 
  
 
Supplementary Figure 5 – Mouse organs dissected from mice sacrificed at thirty minutes. A – 
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